

CITATION REPORT

List of articles citing

Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

DOI: 10.1093/ndt/gfk062

Nephrology Dialysis Transplantation, 2006, 21, 1104-8.

Source: <https://exaly.com/paper-pdf/40976789/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1528	Diffusion-weighted MRI of focal renal masses. 46-54		
1527	MRI of the Abdomen. 568-585		
1526	Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?. 2006 , 61, 905-6		123
1525	Bibliography. Current world literature. Dialysis and transplantation. 2006 , 15, 648-63		
1524	Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). 2006 , 18, 614-7		116
1523	Current awareness: Pharmacoepidemiology and drug safety. 2006 , 15, i-xii		
1522	Nephrogenic systemic fibrosis: an emerging threat among renal patients. 2006 , 19, 191-4		39
1521	Briefly Noted. 2006 , 19, 447-448		
1520	Nephrogenic fibrosing dermopathy and calciphylaxis with pseudoxanthoma elasticum-like changes. 2006 , 33, 695-700		37
1519	Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. 2006 , 16, 2619-21		266
1518	Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. 2006 , 6, 2212-7		76
1517	The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy--report of two cases and review of the literature. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 631-6	4-3	22
1516	Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. 2006 , 17, 2359-62		1054
1515	Nephrogenic systemic fibrosis and gadolinium-based contrast agents. 2007 , 2, 593-605		5
1514	What nephrologists need to know about gadolinium. 2007 , 3, 654-68		254
1513	Theory, technique, and practice of magnetic resonance angiography. 2007 , 15, 376-83		5
1512	Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. 2007 , 357, 720-2		99

1511	Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. 2007 , 80, 73-6		152
1510	Peripheral arterial disease: a guide for nephrologists. 2007 , 2, 839-46		47
1509	Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing's sarcoma, end-stage renal disease, and hemodialysis. 2007 , 10, 395-402		26
1508	Case-control study of gadodiamide-related nephrogenic systemic fibrosis. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 3174-8	4-3	171
1507	Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 1233-40	4-3	32
1506	What about the GPs? We're still great for continuity. 2007 , 334, 1336		
1505	What about the GPs? We help treat acute coronary syndromes. 2007 , 334, 1336		
1504	Gadolinium contrast may be risky in kidney disease. 2007 , 334, 1335-6		0
1503	Magnetic resonance imaging of the liver: a review. 2007 , 1, 213-23		2
1502	A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. 2007 , 3, 111-5		23
1501	[Nephrogenic systemic fibrosis--a new interdisciplinary challenge]. 2007 , 132, 2706-10		3
1500	[Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper]. 2007 , 179, 613-7		19
1499	Nephrogenic systemic fibrosis: risk factors and incidence estimation. 2007 , 243, 148-57		1162
1498	Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. 2007 , 242, 647-9		485
1497	Are patients with moderate renal failure at risk for developing nephrogenic systemic fibrosis?. 2007 , 244, 930-1; author reply 931-2		14
1496	Navigator-gated MR angiography of the renal arteries: a potential screening tool for renal artery stenosis. 2007 , 188, W540-6		50
1495	Increased signal in the subarachnoid space on fluid-attenuated inversion recovery imaging associated with the clearance dynamics of gadolinium chelate: a potential diagnostic pitfall. 2007 , 28, 1964-7		33
1494	Nephrogenic systemic fibrosis and nonionic linear chelates. 2007 , 188, W580; author reply W581		11

1493	Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. 2007 , 188, 586-92	482
1492	Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: clinical aspects. 2007 , 6, 24-7	7
1491	Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. 2007 , 41, 1481-5	48
1490	Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link?. 2007 , 2, 200-2	79
1489	New insights into nephrogenic systemic fibrosis. 2007 , 18, 2636-43	103
1488	Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. 2007 , 2, 264-7	196
1487	Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?. 2007 , 48, 593-6	49
1486	The Detection and Characterization of Nanoparticulate Heavy Metals in Epithelial Tissues in Patients with Nephrogenic Fibrosing Dermopathy. 2007 , 1063, 1	1
1485	Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. 2007 , 2, 258-63	103
1484	Management of suspected acute pulmonary embolism in the era of CT angiography: a statement from the Fleischner Society. 2007 , 245, 315-29	432
1483	[Nephrogenic systemic fibrosis and gadolinium-based contrast media]. 2007 , 62, 169-72	4
1482	MTAS: Mental health of applicants seems to be deteriorating. 2007 , 334, 1335	11
1481	Gadolinium--specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. 2007 , 2007, 182-184	1
1480	Exploration de l'appareil urinaire chez l'enfant. 2007 , 2, 1-17	
1479	Do Recent Advances in MR Technologies Contribute to Better Gamma Knife Radiosurgery Treatment Results for Brain Metastases?. 2007 , 20, 481-90	6
1478	Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 3179-85	4-3 97
1477	Nephrogenic systemic fibrosis--the need for a multidisciplinary approach. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 3097-101	4-3 6
1476	The role of the hospital dermatologist in the diagnosis and treatment of calciphylaxis and nephrogenic systemic fibrosis. 2007 , 26, 163-7	19

1475	Gadolinium and nephrogenic systemic fibrosis. 2007 , 72, 260-4	202
1474	Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney disease. 2007 , 120, 561-2	38
1473	Development of Serious and Sometimes Fatal Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy. 2007 , 26, 29-30	2
1472	Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. 2007 , 56, 21-6	401
1471	Gadolinium deposition in nephrogenic fibrosing dermopathy. 2007 , 56, 27-30	297
1470	Nephrogenic systemic fibrosis: a clinicopathologic study of six cases. 2007 , 57, 105-11	49
1469	Diabetic myonecrosis in an orthotopic heart transplant recipient. 2007 , 26, 549-52	3
1468	[Nephrogenic systemic fibrosis: more hard times for renal failure patients]. 2007 , 3, 152-6	8
1467	[Nephrogenic systemic fibrosis and gadolinium-containing contrast agents: what imaging for chronic kidney failure patients?]. 2007 , 3, 123-5	1
1466	Abdominal MRI advances in the detection of liver tumours and characterisation. 2007 , 8, 525-35	54
1465	Radiologic assessment of acute and chronic pancreatitis. 2007 , 87, 1341-58, viii	48
1464	Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients. 2007 , 41, 565-6	13
1463	ACR guidance document for safe MR practices: 2007. 2007 , 188, 1447-74	562
1462	Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. 2007 , 245, 168-75	260
1461	Kidneys and MR urography. 2007 , 15, 373-82, vii	6
1460	Abdominal and pelvic MR angiography. 2007 , 15, 301-14, v-vi	11
1459	Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. 2007 , 23, 131-54	60
1458	Fibrose systhique nephrogique et gadolinium. 2007 , 2007, 9	

1457	Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency. 2007 , 18, 331-3	24
1456	Nephrogenic Fibrosing Dermopathy/Nephrogenic Systemic Fibrosis (NFD/NSF) and Gadolinium-Based Magnetic Resonance Contrast Agents (GBMCAs): A Literature Review. 2007 , 38, 51-55	
1455	[Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis: role of gadolinium?]. 2007 , 134, 667-71	15
1454	Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. 2007 , 143, 1025-30	81
1453	Effects of Coffee and Napping on Nighttime Highway Driving. 2007 , 146, 229	
1452	NHS independence: An NHS board is the way forward. 2007 , 334, 1336	
1451	Erythropoietin, gadolinium, and nephrogenic fibrosing dermopathy. 2007 , 146, 229-30; author reply 230	4
1450	Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. 2007 , 56, 3433-41	158
1449	Nephrogenic systemic fibrosis and gadolinium exposure: association and lessons for idiopathic fibrosing disorders. 2007 , 56, 3173-5	37
1448	Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. 2007 , 2, 199-205	149
1447	Venous outflow obstruction in liver transplantation is associated with the anastomotic technique. 2007 , 13, 1751-2	
1446	Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI. 2007 , 25, 900-9	161
1445	MR colonography with fecal tagging: do individual patient characteristics influence image quality?. 2007 , 25, 1007-12	5
1444	MR contrast agents: physical and pharmacologic basics. 2007 , 25, 884-99	193
1443	Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. 2007 , 25, 881-3	33
1442	Safety risks with gadolinium-based contrast agents. 2007 , 26, 816; author reply 817	4
1441	Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. 2007 , 26, 1190-7	210
1440	Nephrogenic systemic fibrosis: center case review. 2007 , 26, 1198-203	94

1439	Nephrogenic systemic fibrosis: Summary of the special symposium. 2007 , 26, 1179-1181	4
1438	The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. 2007 , 87, 858-70	350
1437	Nephrogenic systemic fibrosis associated with gadolinium-containing contrast media administration in patients with reduced glomerular filtration rate. 2007 , 51, 300	4
1436	Update on radiological imaging of renal cell carcinoma. 2007 , 99, 1217-22	45
1435	Nephrogenic systemic fibrosis associated with gadolinium-containing contrast media administration in patients with reduced glomerular filtration rate. 2007 , 12, 111	13
1434	Nephrogenic systemic fibrosis: is any contrast safe in renal failure?. 2007 , 37, 429-31	9
1433	Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum. 2007 , 156, 473-9	35
1432	Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. 2007 , 157, 783-7	50
1431	Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. 2008 , 158, 273-80	156
1430	Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. 2008 , 158, 607-10	25
1429	Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature. 2007 , 32, 353-8	35
1428	Gadolinium use in patients with kidney disease: a cause for concern. 2007 , 20, 179-85	61
1427	Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. 2007 , 7, 2425-32	81
1426	Nephrogenic systemic fibrosis: a nephrologist's perspective. 2007 , 11 Suppl 3, S2-6	5
1425	Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. 2007 , 17, 1921-3	27
1424	ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. 2007 , 17, 2692-6	120
1423	[Nephrogenic systemic fibrosis. Medical detective work in the 21st century]. 2007 , 66, 533-5	8
1422	CT and MRI of paediatric Crohn disease. 2007 , 37, 1083-92	36

1421	[Nephrogenic systemic fibrosis (NSF)–implications for radiology]. 2007 , 47, 785-93	17
1420	[Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging]. 2007 , 47, 794-9	4
1419	[Nephrogenic systemic fibrosis]. 2007 , 47, 778-84	10
1418	Imaging in the time of NFD/NSF: do we have to change our routines concerning renal insufficiency?. 2007 , 20, 57-62	40
1417	Nephrogene systemische Fibrose (NSF) nach Applikation gadoliniumhaltiger Kontrastmittel bei Shuntpatienten. 2007 , 12, 449-454	1
1416	Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. 2007 , 22, 1395	35
1415	Good MRI images: to Gad or not to Gad?. 2007 , 22, 1239-42	18
1414	Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis?. 2007 , 119, 271-5	9
1413	Nephrogene systemische Fibrose. 2007 , 2, 449-451	
1412	Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. 2008 , 21, 469-90	280
1411	Nephrogenic systemic fibrosis: an emerging entity. 2008 , 40, 715-24	21
1410	Nephrogenic systemic fibrosis. 2008 , 38 Suppl 1, S125-9	19
1409	Gadolinium and nephrogenic systemic fibrosis: time to tighten practice. 2008 , 38, 489-96; quiz 602-3	71
1408	Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. 2008 , 37, 457-64	26
1407	Gadolinium-enhanced angiography for diagnosis and interventional treatment of subclavian artery stenosis prior to fistula creation. 2008 , 31 Suppl 2, S48-52	1
1406	Anti-neutrophil cytoplasmic antibody (c-ANCA) positive recurrent eosinophilic fasciitis responsive to cyclophosphamide: a clinical pathology conference held by the Division of Rheumatology at Hospital for Special Surgery. 2008 , 4, 81-6	7
1405	Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. 2008 , 10, 195-204	23
1404	Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure. 2008 , 12, 403-406	15

1403	Summary of the safety data for Gadobutrol and Gadofosveset. 2008 , 18, 47-53	1
1402	Application of magnetic resonance urography in diagnosis of congenital urogenital anomalies in children. 2008 , 24, 979-86	27
1401	Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents. 2008 , 23, 2121-9	38
1400	Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. 2008 , 214, 584-93	104
1399	Non-contrast-enhanced MR angiography of the thoracic aorta using cardiac and navigator-gated magnetization-prepared three-dimensional steady-state free precession. 2008 , 27, 504-9	41
1398	3D nongadolinium-enhanced ECG-gated MRA of the distal lower extremities: preliminary clinical experience. 2008 , 28, 181-9	86
1397	Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies. 2008 , 28, 797-804	21
1396	Kidney transplantation: structural and functional evaluation using MR Nephro-Urography. 2008 , 28, 805-22	29
1395	Functional assessment of the kidney from magnetic resonance and computed tomography renography: impulse retention approach to a multicompartament model. 2008 , 59, 278-88	57
1394	In vitro characterization of phosphatidylglycerol-based thermosensitive liposomes with encapsulated ¹ H MR T1-shortening gadodiamide. 2008 , 3, 19-26	21
1393	What Causes Nephrogenic Systemic Fibrosis?. 2008 , 37, 95-98	2
1392	Extracorporeal photopheresis improves nephrogenic fibrosing dermatopathy/nephrogenic systemic fibrosis: three case reports and review of literature. 2008 , 23, 144-50	48
1391	Imatinib mesylate treatment of nephrogenic systemic fibrosis. 2008 , 58, 2543-8	124
1390	Nephrogenic systemic fibrosis. 2008 , 51, 214-5	1
1389	Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. 2008 , 176, 54-7	43
1388	Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. 2008 , 248, 77-88	120
1387	Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T. 2008 , 18, 1260-8	28
1386	Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. 2008 , 18, 2164-73	165

1385	Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial. 2008 , 18, 2610-9	25
1384	Gadolinium - is it to blame?. 2008 , 35, 520-2	9
1383	High-molar contrast agents for CNS application. 2008 , 11, 26-32	4
1382	Nephrogenic Systemic Fibrosis. 2008 , 11, 13-18	5
1381	Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer. 2008 , 34, 483-97	12
1380	Nephrogenic systemic fibrosis: early recognition and treatment. 2008 , 21, 123-8	52
1379	Nephrogenic systemic fibrosis: non-gadolinium options for the imaging of CKD/ESRD patients. 2008 , 21, 160-5	16
1378	Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease. 2008 , 21, 171-3	11
1377	Tissue deposition of gadolinium and development of NSF: a convergence of factors. 2008 , 21, 150-4	27
1376	Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure. 2008 , 21, 135-9	42
1375	Treatment of nephrogenic systemic fibrosis: limited options but hope for the future. 2008 , 21, 155-9	22
1374	Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?. 2008 , 21, 129-34	51
1373	Nephrogenic systemic fibrosis and gadolinium-based contrast: what's a nephrologist to do?. 2008 , 21, 121-2	0
1372	Gadolinium and nephrogenic systemic fibrosis: association or causation. 2008 , 13, 235-41	27
1371	Nephrogenic systemic fibrosis in a gadolinium-naive renal transplant recipient. 2008 , 49, 44-7	27
1370	Nephrogenic systemic fibrosis and the role of gadolinium contrast media. 2008 , 52, 339-50	20
1369	Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. 2008 , 22, 803-8	34
1368	A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?. 2008 , 158, 1358-62	13

1367	Nephrogenic systemic fibrosis: a histopathological study of eight cases of a recently described entity. 2008 , 52, 531-4	6
1366	Magnetic resonance imaging with gadolinium enhancement in renal failure: a need for caution. 2008 , 47, 947-9	2
1365	Absence of human herpes virus-8 (HHV8) in nephrogenic systemic fibrosis. 2008 , 1, 82	1
1364	Visualization of the cardiac venous system using cardiac magnetic resonance. 2008 , 101, 407-12	66
1363	Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. 2008 , 51, 966-75	76
1362	Adverse drug reactions. 2008 , 36, 364-368	1
1361	Speciation analysis of gadolinium-based MRI contrast agents in blood plasma by hydrophilic interaction chromatography/electrospray mass spectrometry. 2008 , 80, 8163-70	44
1360	Successful pregnancy in a hemodialysis patient and marked resolution of her nephrogenic systemic fibrosis. 2008 , 51, e29-32	9
1359	Patterns of late gadolinium enhancement in chronic hemodialysis patients. 2008 , 1, 450-6	33
1358	Nephrogenic systemic fibrosis: considerations for the cardiologist. 2008 , 1, 457-9	2
1357	Magnetic resonance cardiac vein imaging: relation to mitral valve annulus and left circumflex coronary artery. 2008 , 1, 729-38	28
1356	Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. 2008 , 180, 830-5; discussion 835	50
1355	Scleroderma-like fibrosing disorders. 2008 , 34, 199-220; ix	79
1354	Treatment of complex stenoses involving renal artery bifurcations with use of drug-eluting stents. 2008 , 19, 272-8	14
1353	Nephrogenic systemic fibrosis with septal panniculitis mimicking erythema nodosum. 2008 , 58, 149-50	46
1352	Dermatologic, periodontal, and skeletal manifestations of Haim-Munk syndrome in two siblings. 2008 , 58, 339-44	24
1351	Treatment of nephrogenic systemic fibrosis with Re-PUVA. 2008 , 59, S39-40	11
1350	Localized nephrogenic fibrosing dermopathy: Aberrant dermal repairing?. 2008 , 58, 336-9	14

1349	Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. 2008 , 59, 356-8	16
1348	Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. 2008 , 58, 1025-30	26
1347	Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. 2008 , 59, 218-24	47
1346	Gadolinium-enhanced computed tomography cystogram to diagnose bladder augment rupture in patients with iodine sensitivity. 2008 , 71, 984.e9-11	8
1345	Clinical and histological findings in nephrogenic systemic fibrosis. 2008 , 66, 191-9	101
1344	MRI contrast media are used to improve visualization of abnormal structures or lesions in various parts of the body. Introduction. 2008 , 66, 153-9	5
1343	Nephrogenic systemic fibrosis--implications for nephrologists. 2008 , 66, 208-12	15
1342	Reducing the risk of iodine-based and MRI contrast media administration: recommendation for a questionnaire at the time of booking. 2008 , 66, 225-9	14
1341	Magnetic resonance angiography (MRA) in renally impaired patients: when and how. 2008 , 66, 213-9	32
1340	An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. 2008 , 66, 187-90	34
1339	Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. 2008 , 66, 230-4	236
1338	Cutaneous manifestations of chronic kidney disease. 2008 , 26, 255-64	47
1337	Gadolinium Endohedral Metallofullerene-Based MRI Contrast Agents. 2008 , 157-180	11
1336	Imaging assessment of acute pancreatitis: a review. 2008 , 29, 322-40	28
1335	Magnetic resonance urography in pediatric urology. 2008 , 4, 74-82; quiz 82-3	32
1334	Atheromatous renovascular disease: overview and challenges. 2008 , 34, 179-90	2
1333	Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. 2008 , 3027-47	410
1332	Gadofullerene MRI contrast agents. 2008 , 3, 201-13	192

1331	Nephrogenic systemic fibrosis associated with gadolinium use. 2008 , 107, 270-4	16
1330	Magnetic resonance nephrourography: current and developing techniques. 2008 , 46, 11-24, v	19
1329	When should abdominal magnetic resonance imaging be used?. 2008 , 6, 610-5	10
1328	Secondary causes of hypertension. 2008 , 35, 489-500, vi	12
1327	Preliminary study of the use of drug-eluting stents in atherosclerotic renal artery stenoses 4 mm in diameter or smaller. 2008 , 19, 833-9	26
1326	Gadolinium-containing MRI contrast agents: important variations on a theme for NSF. 2008 , 5, 29-35	49
1325	Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. 2008 , 358, 827-38	51
1324	The impact of NSF on the care of patients with kidney disease. 2008 , 5, 45-52	37
1323	Assessment of renal function with dynamic contrast-enhanced MR imaging. 2008 , 16, 597-611, viii	55
1322	Preoperative mapping venography in patients who require hemodialysis access: imaging findings and contribution to management. 2008 , 19, 1027-33	19
1321	Non-contrast-enhanced MR imaging of the renal arteries. 2008 , 16, 573-84, vii	13
1320	Nephrogenic systemic fibrosis: an overview. 2008 , 5, 23-8	55
1319	Impact on hospital policy: Yale experience. 2008 , 5, 53-6	9
1318	Diffusion-weighted MR imaging of the kidneys and the urinary tract. 2008 , 16, 585-96, vii-viii	38
1317	Which Study When? Is Gadolinium-enhanced MR Imaging Safer than Iodine-enhanced CT?1. 2008 , 249, 3-8	23
1316	Hydrochalarones: a novel endohedral metallofullerene platform for enhancing magnetic resonance imaging contrast. 2008 , 51, 3681-3	54
1315	Stem cell labeling for magnetic resonance imaging. 2008 , 17, 132-42	40
1314	Characterization of aneurysm remnants after endovascular treatment: contrast-enhanced MR angiography versus catheter digital subtraction angiography. 2008 , 29, 1570-4	55

1313	CT and MR imaging of progressive dural involvement by nephrogenic systemic fibrosis. 2008 , 29, 1880-2		15
1312	3D time-resolved MR angiography (MRA) of the carotid arteries with time-resolved imaging with stochastic trajectories: comparison with 3D contrast-enhanced Bolus-Chase MRA and 3D time-of-flight MRA. 2008 , 29, 1847-54		141
1311	Nephrogenic systemic fibrosis: more questions and some answers. 2008 , 110, c24-31; discussion c32		41
1310	Acute phase reaction to gadolinium-DTPA in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 1274-7	4-3	8
1309	Nephrogenic systemic fibrosis: possible association with a predisposing infection. 2008 , 190, 1069-75		21
1308	Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 856-63	4-3	114
1307	Management of the incidental renal mass. 2008 , 249, 16-31		307
1306	Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. 2008 , 3, 968-75		64
1305	MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis. 2008 , 191, 1129-39		168
1304	Radiological contrast agents. 2008 , 533-543		
1303	Progressive arm and leg stiffness in a patient with chronic renal impairment. 2008 , 4, 557-62		7
1302	MRI in patients with chronic obstructive uropathy and compromised renal function: a sole method for morphological and functional assessment. 2008 , 81, 624-9		11
1301	How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?. 2008 , 3, 649-51		19
1300	Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. 2008 , 67 Suppl 3, iii66-9		27
1299	Contrast-enhanced ultrasonography with microbubbles for successful screening of kidney tumours. 2008 , 1, 469-470		
1298	Noninvasive imaging of quantitative cerebral blood flow changes during 100% oxygen inhalation using arterial spin-labeling MR imaging. 2008 , 29, 663-7		30
1297	Incidence of nephrogenic systemic fibrosis at two large medical centers. 2008 , 248, 807-16		241
1296	Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. 2008 , 3, 747-51		81

1295	Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. 2008 , 248, 799-806	148
1294	Nephrogenic systemic fibrosis: a new concern for rheumatologists. 2008 , 4, 445	
1293	MR angiography of the lower extremities. 2008 , 190, 1675-84	47
1292	Nephrogenic systemic fibrosis: a report of 29 cases. 2008 , 190, 736-41	99
1291	MR urography: techniques and clinical applications. 2008 , 28, 23-46; discussion 46-7	126
1290	Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. 2008 , 190, 1060-8	124
1289	Nephrogenic systemic fibrosis: the story unfolds. 2008 , 73, 1335-7	14
1288	Which study when? Iodinated contrast-enhanced CT versus gadolinium-enhanced MR imaging. 2008 , 249, 9-15	34
1287	Nonenhanced MR angiography. 2008 , 248, 20-43	324
1286	Nephrogenic systemic fibrosis and gadolinium: a perfect storm. 2008 , 191, 1150-3	19
1285	Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation. 2008 , 2008, 151-153	1
1284	Cranial Neuropathy as a Presenting Sign of Recurrent Aggressive Skin Cancer. 2008 , 34, 483-497	9
1283	Clinical role of non-contrast magnetic resonance angiography for evaluation of renal artery stenosis. 2008 , 72, 1627-30	44
1282	Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. 2008 , 3, 67-75	126
1281	Indications for Adult and Pediatric Magnetic Resonance Imaging Gadolinium-Enhanced Cisternography and Myelography: Experience and Review of the Literature. 2008 , 4, 170-180	5
1280	Implications of NSF-active and NSF-inert in nephrogenic systemic fibrosis. 2008 , 191, 1864-6	2
1279	Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. 2008 , 43, 817-28	398
1278	Nephrogenic systemic fibrosis: epidemiology update. 2008 , 7, 367-371	

1277	Imaging of the intracranial venous system. 2008 , 14, 12-22	51
1276	Nephrogenic systemic fibrosis: epidemiology update. 2008 , 17, 315-9	28
1275	Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists. 2008 , 32, 1-3	14
1274	High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. 2008 , 43, 141-4	200
1273	Magnetic resonance angiography of the extracranial carotid system. 2008 , 19, 241-9	16
1272	The Effects of Transplantation on Preexisting Dermatoses. 113-118	
1271	Nefropatia induzida por contraste: avaliaçã da proteçã pela n-acetilcisteïna e alopurinol em ratos uninefrectomizados. 2008 , 41, 177-181	3
1270	Radiological Central Vein Treatment in Vascular Access. 2008 , 9, 85-101	25
1269	Complicaçõs do uso intravenoso de agentes de contraste ^base de gadolõio para ressonãcia magntica. 2008 , 41, 263-267	11
1268	Magnetic Resonance Imaging and Its Usage in Representative Areas of Neurobiological Research. 2008 , 5, 39-48	1
1267	Combination treatment with plasmapheresis and sirolimus does not seem to benefit nephrogenic systemic fibrosis. 2008 , 31, 913-4	12
1266	Contrast Media in Urogenital Radiology. 2009 , 76, 10-18	1
1265	Large sample of nephrogenic systemic fibrosis cases from a single institution. 2009 , 145, 1095-102	18
1264	[Imaging for hepato-pancreatico-biliary diseases - a short review]. 2009 , 66, 31-8	
1263	Nephrogenic systemic fibrosis: late skin manifestations. 2009 , 145, 183-7	22
1262	Detection of clonal T cells in the circulation of patients with nephrogenic systemic fibrosis. 2009 , 145, 1164-9	7
1261	Non-contrast MRI for the evaluation of hydronephrotic and dysfunctioning kidney secondary to testicular cancer. 2009 , 31, 153-8	1
1260	Safety first: Recognizing and managing the risks to child participants in magnetic resonance imaging research. 2009 , 16, 153-73	6

1259	Extracellular matrix molecules: potential targets in pharmacotherapy. 2009 , 61, 198-223	350
1258	Three-dimensional electrocardiographically gated variable flip angle FSE imaging for MR angiography of the hands at 3.0 T: initial experience. 2009 , 252, 874-81	24
1257	Magnetic resonance angiography and computed tomography angiography for peripheral arterial disease. 2009 , 21, 85-108	5
1256	Estimates of risk, empirical treatment observations, and unexpected laboratory findings reveal the complexity of nephrogenic systemic fibrosis. 2009 , 145, 1178-82	1
1255	Nephrogenic systemic fibrosis. 2009 , 29, 1-9	40
1254	ECG-gated nonenhanced 3D steady-state free precession MR angiography in assessment of transplant renal arteries: comparison with DSA. 2009 , 252, 914-21	59
1253	Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. 2009 , 253, 390-8	21
1252	Nephrogenic systemic fibrosis and its impact on abdominal imaging. 2009 , 29, 1565-74	73
1251	Features of nephrogenic systemic fibrosis on radiology examinations. 2009 , 193, 61-9	9
1250	Estimation of glomerular filtration rate in dogs by plasma clearance of gadolinium diethylenetriamine pentaacetic acid as measured by use of an ELISA. 2009 , 70, 547-52	10
1249	Erratum. 2009 , 181, 657-657	
1248	Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. 2009 , 253, 689-96	118
1247	Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. 2009 , 250, 371-7	193
1246	High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. 2009 , 192, 1538-43	27
1245	Case report. Appearance of nephrogenic fibrosing dermopathy on a bone scan. 2009 , 82, e35-6	6
1244	The current state of endovascular therapy in the evaluation and management of renovascular disease. 2009 , 26, 333-44	
1243	Is nephrogenic systemic fibrosis linked to the introduction of contrast-enhanced MR angiography?. 2009 , 251, 612-3; author reply 613	3
1242	MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. 2009 , 29, 9-22	52

1241	Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. 2009 , 253, 81-9	85
1240	[Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)]. 2009 , 181, 652-7	19
1239	T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. 2009 , 251, 796-807	95
1238	MRI contrast agent safety in renal impairment. 2009 , 15, 47-53	4
1237	Noninvasive imaging of atheromatous carotid plaques. 2009 , 6, 200-9	11
1236	Case records of the Massachusetts General Hospital. Case 37-2009. A 46-year-old woman with chronic renal failure, leg swelling, and skin changes. 2009 , 361, 2166-76	9
1235	What is the current role of CT urography and MR urography in the evaluation of the urinary tract?. 2009 , 250, 309-23	205
1234	Current status of gadolinium toxicity in patients with kidney disease. 2009 , 4, 461-9	179
1233	Nephrogenic Systemic Fibrosis: Clinical Review and Education for Nurse Practitioners. 2009 , 5, 344-349	4
1232	Dendrimers in medical nanotechnology. 2009 , 28, 12-22	66
1231	Imatinib in the treatment of nephrogenic systemic fibrosis. 2009 , 53, 129-32	41
1230	Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. 2009 , 53, 133-7	31
1229	Clinical testing patterns and cost implications of variation in the evaluation of CKD among US physicians. 2009 , 54, 227-37	27
1228	Classification and basic properties of contrast agents for magnetic resonance imaging. 2009 , 4, 1-23	407
1227	Quantification and excretion kinetics of a magnetic resonance imaging contrast agent by capillary electrophoresis-mass spectrometry. 2009 , 30, 1766-73	24
1226	Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience. 2009 , 29, 887-94	46
1225	Free-breathing diffusion-weighted imaging for the assessment of inflammatory activity in Crohn's disease. 2009 , 29, 880-6	158
1224	Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital. 2009 , 30, 1309-12	10

1223	Diffusion-weighted imaging of the liver: comparison of navigator triggered and breathhold acquisitions. 2009 , 30, 561-8	139
1222	Optimization of the contrast dose and injection rates in whole-body MR angiography at 3.0T. 2009 , 30, 1059-67	13
1221	Role of thermodynamic and kinetic parameters in gadolinium chelate stability. 2009 , 30, 1249-58	135
1220	Risk factors for NSF: a literature review. 2009 , 30, 1298-308	100
1219	Nephrogenic systemic fibrosis: clinical spectrum of disease. 2009 , 30, 1289-97	23
1218	Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. 2009 , 30, 1335-40	30
1217	Renovascular imaging in the NSF Era. 2009 , 30, 1323-34	35
1216	Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?. 2009 , 30, 1236-9	33
1215	Mechanism of NSF: New evidence challenging the prevailing theory. 2009 , 30, 1277-83	39
1214	Removal of gadolinium by dialysis: review of different strategies and techniques. 2009 , 30, 1347-9	14
1213	Nephrogenic systemic fibrosis in liver disease: a systematic review. 2009 , 30, 1313-22	23
1212	Special issue: nephrogenic systemic fibrosis. 2009 , 30, 1233-5	9
1211	STAR and STARFIRE for flow-dependent and flow-independent noncontrast carotid angiography. 2009 , 61, 117-24	20
1210	Improving non-contrast-enhanced steady-state free precession angiography with compressed sensing. 2009 , 61, 1122-31	48
1209	Deep vein thrombosis using noncontrast-enhanced MR venography with electrocardiographically gated three-dimensional half-Fourier FSE: preliminary experience. 2009 , 61, 907-17	25
1208	Non-contrast-enhanced perfusion and ventilation assessment of the human lung by means of fourier decomposition in proton MRI. 2009 , 62, 656-64	195
1207	3D noncontrast MR angiography of the distal lower extremities using flow-sensitive dephasing (FSD)-prepared balanced SSFP. 2009 , 62, 1523-32	89
1206	Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. 2009 , 60, 1508-18	67

1205	Kontrastmittel und Niereninsuffizienz. 2009 , 4, 33-41	
1204	[Hypertension in patients with renal artery stenosis]. 2009 , 50, 42-50	2
1203	Current status of contrast-induced nephropathy and nephrogenic systemic fibrosis in children. 2009 , 39 Suppl 3, 382-4	26
1202	Magnetic resonance urography. 2009 , 34, 527-40	25
1201	Nanoparticles in sentinel lymph node mapping. 2009 , 1, 610-23	42
1200	Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. 2009 , 36, 1244-54	65
1199	Gadolinium-induced nephrogenic systemic fibrosis: communication breakdown among specialists or intuitive stroke of genius?. 2009 , 39, 70-2	
1198	Malignant fibrous histiocytoma complicating nephrogenic systemic fibrosis post liver transplantation. 2009 , 39, 613-7	2
1197	Dermatologic conditions seen in end-stage renal disease. 2009 , 22, 45-55	29
1196	Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy. 2009 , 26, 579-82	20
1195	The correlation between quantitative T2' and regional cerebral blood flow after acute brain ischemia in early reperfusion as demonstrated in a middle cerebral artery occlusion/reperfusion model of the rat. 2009 , 178, 55-8	9
1194	Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT--a pooled analysis of two randomized trials. 2009 , 19, 891-7	67
1193	MRI-guided percutaneous nephrostomy: a feasibility study. 2009 , 19, 1296-301	16
1192	Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. 2009 , 19, 1417-24	62
1191	Tuning the magnetic resonance imaging properties of positive contrast agent nanoparticles by surface modification with RAFT polymers. 2009 , 25, 9487-99	106
1190	Conquering the dark side: colloidal iron oxide nanoparticles. 2009 , 3, 3917-26	77
1189	Hypercalcemia and overexpression of CYP27B1 in a patient with nephrogenic systemic fibrosis: clinical vignette and literature review. 2009 , 24, 1135-9	7
1188	Nephrogenic systemic fibrosis and management of high-risk patients. 2009 , 16, 897-905	33

1187	Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. 2009 , 193, 1044-52	150
1186	Pediatric Nephrology in the ICU. 2009 ,	4
1185	Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. 2009 , 64, 706-13	18
1184	Combined T1-based perfusion MRI and MR angiography in kidney: first experience in normals and pathology. 2009 , 69, 542-9	11
1183	Metal deposition in calcific uremic arteriolopathy. 2009 , 61, 73-9	24
1182	Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options. 2009 , 61, 868-74	27
1181	The year in cardiac imaging. 2009 , 53, 54-70	9
1180	Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. 2009 , 53, 1621-8	140
1179	The role of cardiovascular magnetic resonance imaging in heart failure. 2009 , 54, 1407-24	289
1178	Rehabilitation in nephrogenic systemic fibrosis. 2009 , 1, 684-6	4
1177	Nephrogenic systemic fibrosis in a patient with a p-ANCA systemic vasculitis. 2009 , 5, 264-7	
1176	Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. 2009 , 251, 398-407	262
1175	Pulmonary MR angiography techniques and applications. 2009 , 17, 101-31	12
1174	Dermopatã nefrogãica fibrosante / fibrosis sistãmica nefrogãica. 2009 , 10, 76-82	
1173	Les conditions techniques d'ãutilisation de lãIRM cardiaque. 2009 , 1, 23-33	
1172	Carotid Artery Stenosis. 2009 , 171-182	
1171	Design and function of metal complexes as contrast agents in MRI. 2009 , 61, 63-129	44
1170	Moderate to severe renal impairment cannot be reliably detected from medical history alone: Implications for the use of Gadolinium-based contrast agents. 2009 , 11,	78

1169	Systemic sclerosis: environmental factors. 2009 , 36, 2383-96	47
1168	Polymer-modified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. 2009 , 10, 983-93	232
1167	MRI gadolinium-based contrast agents. Radiologists beware!. 2009 , 67, 335-9	14
1166	Clinical practice. Renal-artery stenosis. 2009 , 361, 1972-8	112
1165	Incorporation of excess gadolinium into human bone from medical contrast agents. 2009 , 1, 479-88	192
1164	[Contrast-enhanced magnetic resonance angiography in congenital heart disease]. 2009 , 51, 261-72	2
1163	Sclerotic bodies in nephrogenic systemic fibrosis: a new histopathologic finding. 2009 , 36, 548-52	20
1162	Magnetic resonance urography update--are we there yet?. 2009 , 30, 246-57	10
1161	Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. 2009 , 47, 855-69, vii	71
1160	Nephrogenic systemic fibrosis: clinical picture and treatment. 2009 , 47, 833-40, vi	34
1159	Contrast medium issues in MR urography. 2009 , 16, 772	2
1158	[Cardiac MRI: technical considerations]. 2009 , 90, 1133-43	4
1157	[Gadolinium-enhanced thoracic CTA: retrospective analysis of image quality and tolerability in 45 patients evaluated prior to the description of nephrogenic systemic fibrosis]. 2009 , 90, 287-98	3
1156	Nephrogenic systemic fibrosis: histology and gadolinium detection. 2009 , 47, 841-53, vi-vii	17
1155	Nephrogenic systemic fibrosis: history and epidemiology. 2009 , 47, 827-31, vi	79
1154	How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. 2009 , 47, 871-5, vii	56
1153	Técnicas de imagen en la enfermedad aórtica. 2009 , 16, 299-304	
1152	Nephrogenic systemic fibrosis. 2009 , 17, 159-67	29

1151	Non-contrast-enhanced MR imaging of renal artery stenosis at 1.5 tesla. 2009 , 17, 13-27	22
1150	Analysis of the contrast agent Magnevist and its transmetalation products in blood plasma by capillary electrophoresis/electrospray ionization time-of-flight mass spectrometry. 2009 , 81, 3600-7	33
1149	Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. 2009 , 18, 519-25	36
1148	Ten-year experience with nephrogenic systemic fibrosis: case-control analysis of risk factors. 2009 , 33, 819-23	8
1147	A study of musculoskeletal disease in two chronic hemodialysis populations and its impact on quality of life. 2009 , 15, 405-7	
1146	Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. 2009 , 44, 135-9	48
1145	Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. 2009 , 44, 433-9	31
1144	Comprehensive assessment of renal function and vessel morphology in potential living kidney donors: an MRI-based approach. 2009 , 44, 705-11	16
1143	Rheumatic manifestations of renal disease. 2009 , 21, 55-61	3
1142	Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial. 2009 , 44, 168-76	34
1141	Dynamic contrast-enhanced perfusion MR imaging with SPIO: a pilot study. 2009 , 44, 503-8	5
1140	Left ventricular infarct size assessed with 0.1 mmol/kg of gadobenate dimeglumine correlates with that assessed with 0.2 mmol/kg of gadopentetate dimeglumine. 2009 , 33, 328-33	12
1139	Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. 2009 , 44, 74-81	67
1138	In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model. 2009 , 44, 265-70	23
1137	Peripheral magnetic resonance angiography with continuous table movement in combination with high spatial and temporal resolution time-resolved MRA With a total single dose (0.1 mmol/kg) of gadobutrol at 3.0 T. 2009 , 44, 627-33	52
1136	Magnetic resonance urography in pediatric urology. 2010 , 20, 323-9	23
1135	Pharmacovigilance – The Crucial Role of Health Care Professionals Case Study: Gadolinium and Nephrogenic Systemic Fibrosis. 2010 , 6, 180-183	
1134	Differentiation of Bosniak categories IIF and III cystic masses: what radiologists should know. 2010 , 34, 847-54	9

1133	Gadolinium Based Contrast Agents and NSF. 2010 , 6, 189-192	
1132	Is Nephrogenic Systemic Fibrosis a Disease of Fibrocytes?. 2010 , 6, 171-175	
1131	Minimization of MR contrast weightings for the comprehensive evaluation of carotid atherosclerotic disease. 2010 , 45, 36-41	24
1130	Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. 2010 , 45, 42-8	15
1129	Nephrogenic systemic fibrosis. 2010 , 22, 54-8	19
1128	Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. 2010 , 45, 733-9	20
1127	Radiological contrast agents. 2010 , 843-864	
1126	The "Connective Tissue Diseases" 2010 , 1-138	9
1125	Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. 2010 , 20, 218-26	15
1124	Retrospective analysis of patients for development of nephrogenic systemic fibrosis following conventional angiography using gadolinium-based contrast agents. 2010 , 20, 595-603	13
1123	The fate of Gd and chelate following intravenous injection of gadodiamide in rats. 2010 , 20, 1636-43	14
1122	Differentiation between hepatic haemangiomas and cysts with an inversion recovery single-shot turbo spin-echo (SSTSE) sequence using the TI nulling value of hepatic haemangioma with sensitivity encoding. 2010 , 20, 2241-7	1
1121	Surface Modification of Positive Contrast Nanoparticle Agents with RAFT Polymers Towards the Targeted Imaging and Treatment of Cancer. 2010 , 65-101	2
1120	[Nephrogenic systemic fibrosis: a rare disease with grave consequences]. 2010 , 51, 39-44	2
1119	[Indications for magnetic resonance imaging in Internal Medicine. When do we really need this technology?]. 2010 , 51, 451-62	1
1118	MR urography in children. Part 1: how we do the F0 technique. 2010 , 40, 732-8	26
1117	Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder. 2010 , 30, 1389-91	4
1116	Contrast-induced nephropathy: pathogenesis and prevention. 2010 , 25, 191-204	40

1115	Imaging features of intramural hematoma of the aorta. 2010 , 26, 65-76	16
1114	ASCI 2010 contrast media guideline for cardiac imaging: a report of the Asian Society of Cardiovascular Imaging cardiac computed tomography and cardiac magnetic resonance imaging guideline working group. 2010 , 26, 203-12	10
1113	Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. 2010 , 55, 1040-9	14
1112	Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008. 2010 , 56, 458-67	24
1111	Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?. 2010 , 56, 427-30	11
1110	Bladder cancer in 2010: how far have we come?. 2010 , 60, 244-72	248
1109	The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. 2010 , 10, 558-62	18
1108	Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. 2010 , 31, 440-6	90
1107	Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis: results of a phase III multicenter trial. 2010 , 31, 390-7	16
1106	Fully automated reconstruction of ungated ghost magnetic resonance angiograms. 2010 , 31, 655-62	1
1105	Non-contrast renal artery MRA using an inflow inversion recovery steady state free precession technique (Inhance): comparison with 3D contrast-enhanced MRA. 2010 , 31, 1411-8	71
1104	Effective use of flow-spoiled FBI and time-SLIP methods in the diagnostic study of an aberrant vessel of the head and neck: "left jugular venous steal by the right jugular vein". 2010 , 32, 429-33	6
1103	Nephrogenic systemic fibrosis: what the hospitalist needs to know. 2010 , 5, 46-50	13
1102	Fast inversion recovery magnetic resonance angiography of the intracranial arteries. 2010 , 63, 1648-58	8
1101	Novel sorbents for removal of gadolinium-based contrast agents in sorbent dialysis and hemoperfusion: preventive approaches to nephrogenic systemic fibrosis. 2010 , 6, 1-8	41
1100	Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?. 2010 , 14, 289-94	7
1099	Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. 2010 , 37, 204-10	26
1098	Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. 2010 , 163, 1077-81	46

1097	Evaluation of gadolinium-enhanced T1-weighted magnetic resonance imaging in the preoperative assessment of local staging in rectal cancer. 2010 , 12, 1139-48	25
1096	MISCELLANEOUS TUMOR-LIKE LESIONS, AND HISTIOCYTIC AND FOREIGN BODY REACTIONS. 965-981	
1095	Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data. 2010 , 2, 427-33	19
1094	Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium-cluster-fullerene-conjugate: a new chance in cancer diagnostics. 2010 , 7, 136-46	42
1093	Cardiovascular Magnetic Resonance Contrast Agents. 2010 , 76-90	3
1092	DW-MRI of the urogenital tract: applications in oncology. 2010 , 10 Spec no A, S112-23	25
1091	Toxicité des chélates de gadolinium chez le patient insuffisant rénal. 2010 , 22, 90-95	1
1090	Exophytic renal masses: angular interface with renal parenchyma for distinguishing benign from malignant lesions at MR imaging. 2010 , 255, 501-7	47
1089	NFB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. 2010 , 69, 2024-33	35
1088	Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices. 2010 , 5, 964-71	6
1087	Macromolecular and dendrimer-based magnetic resonance contrast agents. 2010 , 51, 751-67	61
1086	Comparative studies of different gadolinium agents in brain tumors: differences between gadolinium chelates and their possible influence on imaging features. 2010 , 31, 981-2	8
1085	Nephrogenic systemic fibrosis following acute kidney injury and exposure to gadolinium. 2010 , 64, 33-6	2
1084	Evolving role of magnetic resonance imaging in renal cancer imaging. 2010 , 24, 707-11	2
1083	Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. 2010 , 69, 2017-23	32
1082	MR imaging in multiple sclerosis: review and recommendations for current practice. 2010 , 31, 983-9	77
1081	Cutaneous mucinosis. 2010 , 353-367.e10	2
1080	Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. 2010 , 51, 1126-36	49

1079	Nephrogenic systemic fibrosis (NSF): the role of tamoxifen. 2010 , 3, 505	2
1078	The five most cited NDT papers from 2005 to 2009. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 2825-313	
1077	Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. 2010 , 83, 590-5	23
1076	Gadolinium-enhanced coronary CT angiography: improved safety?. 2010 , 96, 1513-5	1
1075	Nephrogenic systemic fibrosis following hair-dye ingestion induced acute renal failure. 2010 , 76, 400-3	4
1074	Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. 2010 , 256, 735-43	46
1073	Nonenhanced free-breathing ECG-gated steady-state free precession 3D MR angiography of the renal arteries: comparison between 1.5 T and 3 T. 2010 , 194, 794-8	27
1072	Screening patients to assess renal function before administering gadolinium chelates: assessment of the Choyke questionnaire. 2010 , 195, 424-8	19
1071	Assessment of chronic renal allograft nephropathy using contrast-enhanced MRI: a pilot study. 2010 , 194, W407-13	13
1070	Breast MR imaging: current indications and advanced imaging techniques. 2010 , 48, 1013-42	45
1069	MRI of carotid atherosclerosis: clinical implications and future directions. 2010 , 7, 165-73	119
1068	Diffusion-weighted MRI and liver metastases. 2010 , 18, 451-64, x	18
1067	[MRI and the thorax]. 2010 , 27, 395-402	2
1066	Low-dose, time-resolved, contrast-enhanced 3D MR angiography in the assessment of the abdominal aorta and its major branches at 3 Tesla. 2010 , 17, 564-76	18
1065	Pediatric urologic advanced imaging: techniques and applications. 2010 , 37, 307-18	12
1064	Disorders of Connective Tissue. 2010 , 1-70	9
1063	Functionalized nanoporous silica for the removal of heavy metals from biological systems: adsorption and application. 2010 , 2, 2749-58	102
1062	Contrast Media-Induced Nephropathy and Nephrogenic Systemic Fibrosis. 2010 , 831-844	1

1061	Diffusion-weighted MR imaging of the liver. 2010 , 254, 47-66	621
1060	High relaxivity trimetallic nitride (Gd ₃ N) metallofullerene MRI contrast agents with optimized functionality. 2010 , 21, 610-5	117
1059	Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. 2010 , 110, 2921-59	519
1058	Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?. 2010 , 62, 337-42	11
1057	Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. 2010 , 62, 38-44	32
1056	The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. 2010 , 63, 483-9	20
1055	Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience. 2010 , 63, 389-99	11
1054	MRI safety: nephrogenic systemic fibrosis and other risks. 2010 , 17, 1097-104	37
1053	Contrast media use in the operating room. 2010 , 25, 94-103	8
1052	Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media. 2010 , 65, 636-41	11
1051	Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. 2010 , 73, 357-9	37
1050	Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease. 2010 , 76, 129-34	34
1049	Nanotechnology and dermatology: part II--risks of nanotechnology. 2010 , 28, 581-8	24
1048	Nephrogenic systemic fibrosis presenting as myopathy: a case report with histopathologic correlation. 2010 , 20, 411-3	7
1047	Gadolinium-promoted precipitation of calcium phosphate is associated with profibrotic activation of RAW 264.7 macrophages. 2010 , 24, 1743-9	17
1046	Contrast material for abdominal dynamic contrast-enhanced 3D MR angiography with parallel imaging: intraindividual equimolar comparison of a macrocyclic 1.0 M gadolinium chelate and a linear ionic 0.5 M gadolinium chelate. 2010 , 194, 821-9	29
1045	Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. 2010 , 45, 769-77	32
1044	Magnetic resonance nephrourography: current and developing techniques. 2010 , 18, 29-42	

1043	Macrocyclic Gd ³⁺ chelates attached to a silsesquioxane core as potential magnetic resonance imaging contrast agents: synthesis, physicochemical characterization, and stability studies. 2010 , 49, 6124-38		52
1042	Nanotechnology and MRI contrast enhancement. 2010 , 2, 491-502		64
1041	Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. 2010 , 10, 133-45		34
1040	Contemporary applications and limitations of magnetic resonance imaging contrast materials. 2010 , 183, 27-33		22
1039	Speciation of gadolinium based MRI contrast agents in environmental water samples using hydrophilic interaction chromatography hyphenated with inductively coupled plasma mass spectrometry. 2010 , 25, 55-61		41
1038	Contrast agents used in cardiovascular magnetic resonance imaging: current issues and future directions. 2010 , 10, 227-37		6
1037	Identification and characterization of gadolinium(III) complexes in biological tissue extracts. 2010 , 2, 490-7		16
1036	Simple and rapid quantification of gadolinium in urine and blood plasma samples by means of total reflection X-ray fluorescence (TXRF). 2011 , 3, 1035-40		37
1035	Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 1099-101	4-3	26
1034	Preliminary study of PASP-USPIO in normal rabbit MR brain perfusion. 2011 ,		
1033	Molecular imaging of cell-based cancer immunotherapy. 2011 , 7, 993-1003		29
1032	Gadolinium-induced nephrogenic systemic fibrosis. 2011 , 31, 310-6		30
1031	Noncontrast MRA for the diagnosis of vascular diseases. 2011 , 29, 341-50		7
1030	L'Utilisation du Gadolinium pour les interventions artérielles. 2011 , 25, 393-403		
1029	[Kidney and iodinated and gadolinium-based contrast agents]. 2011 , 92, 291-8		7
1028	Valor diagnóstico de la resonancia magnética cardiaca en la insuficiencia cardiaca: estado actual. 2011 , 46, 4-12		0
1027	Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. 2011 , 4, 1206-16		77
1026	New insights into the mechanism of abnormal calcification in nephrogenic systemic fibrosis - gadolinium promotes calcium deposition of mesenchymal stem cells and dermal fibroblasts. 2011 , 62, 58-63		9

1025	Nephrogenic systemic fibrosis and gadolinium-based contrast agents. 2011 , 18, 188-98	69
1024	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,	
1023	Incidence of immediate gadolinium contrast media reactions. 2011 , 196, W138-43	199
1022	Imaging in Diagnosis and Staging of Urologic Cancers: Magnetic Resonance Imaging. 2011 , 118-140	
1021	The use of gadolinium for arterial interventions. 2011 , 25, 366-76	8
1020	Imagerie en coupes du coeur et des vaisseaux. 2011 ,	
1019	Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. 2011 , 64, 91-6	49
1018	Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. 2011 , 64, 741-7	12
1017	[Nephrogenic systemic fibrosis and gadolinium contrast agents]. 2011 , 136, 643-5	1
1016	Magnetic Resonance Imaging. 2011 , 439-460	
1015	[Nephrogenic systemic fibrosis]. 2011 , 32, 358-62	6
1014	The pathogenesis of systemic sclerosis. 2011 , 6, 509-37	181
1013	Disordered Mesoporous Gadolinosilicate Nanoparticles Prepared Using Gadolinium Based Ionic Liquid Emulsions: Potential as Magnetic Resonance Imaging Contrast Agents. 2011 , 64, 617	13
1012	THE SYSTEMIC SCLERODERMAS AND RELATED DISORDERS. 2011 , 414-437	
1011	Abdominal and pelvic MR angiography. 47-66	
1010	Magnetic Resonance Imaging and Angiography. 2011 , 195-208	
1009	Breast cancer genes and genetic testing. 202-203	
1008	Gadolinium contrast agent associated stimulation of human fibroblast collagen production. 2011 , 46, 711-7	17

1007	Practical Set-Up. 2011 , 53-67	2
1006	[Skin diseases in hemodialysis and kidney transplant patients]. 2011 , 33, 268-75	0
1005	Comparison of Non-invasive Imaging Studies in the Evaluation of Carotid Artery Stenosis and Occlusion: CT Angiography, Time-of-Flight MR Angiography and Contrast-Enhanced MR Angiography. 2011 , 15, 234	5
1004	Imaging patients with kidney disease: how do we approach contrast-related toxicity?. 2011 , 341, 215-21	18
1003	Clinical study protocol for the ARCH project - computational modeling for improvement of outcome after vascular access creation. 2011 , 12, 369-76	22
1002	The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. 2011 , 46, 807-16	35
1001	Noncontrast magnetic resonance angiography of the hand: improved arterial conspicuity by multidirectional flow-sensitive dephasing magnetization preparation in 3D balanced steady-state free precession imaging. 2011 , 46, 515-23	15
1000	Detection of iron deposition in dermal fibrocytes is a useful tool for histologic diagnosis of nephrogenic systemic fibrosis. 2011 , 33, 271-6	9
999	Exploration de la circulation artfielle. 2011 , 6, 1-30	
998	The use of MRI scanning to triage patients. 2011 , 20, 1310-4	1
997	Safety Considerations in MRI. 2011 ,	
996	Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance. 2011 , 46, 663-71	47
995	Who should have pelvic vessel imaging prior to renal transplantation?. 2011 , 25, 97-103	7
994	Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006. 2011 , 16, 243-8	12
993	Evolution of urological imaging. 2011 , 18, 102-12	13
992	Update on nephrogenic systemic fibrosis: are we making progress?. 2011 , 50, 659-66	20
991	Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark. 2011 , 165, 828-36	36
990	Pathomechanisms of nephrogenic systemic fibrosis: new insights. 2011 , 36, 763-8	13

989	Can gadolinium be given safely to a patient on dialysis?. 2011 , 24, 370-1	7
988	When should nephrectomy be performed for a failed renal transplant?. 2011 , 24, 374-6	
987	What is the role of renal transplantation in a patient with nephrogenic systemic fibrosis?. 2011 , 24, 373-4	3
986	Gadolinium and nephrogenic systemic fibrosis: have we overreacted?. 2011 , 24, 480-6	5
985	Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update. 2011 , 89, 920-3	25
984	What's new in 2011 , 39, 239-241	
983	Assessment of myocardial ischemia with cardiovascular magnetic resonance. 2011 , 54, 191-203	20
982	Screening for breast cancer with sonography. 2011 , 46, 285-91	7
981	Imaging Abdominal Vascular Catastrophes. 2011 , 612-649	
980	Emergency Department Applications of Musculoskeletal Magnetic Resonance Imaging: An Evidence-Based Assessment. 2011 , e1-e33	1
979	Contrast-enhanced magnetic resonance angiography (MRA): evaluation of three different contrast agents at two different doses (0.05 and 0.1 mmol/kg) in pigs at 1.5 Tesla. 2011 , 21, 337-44	7
978	Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?. 2011 , 21, 496-500	18
977	Nonenhanced ECG-gated time-resolved 4D steady-state free precession (SSFP) MR angiography (MRA) for assessment of cerebral collateral flow: comparison with digital subtraction angiography (DSA). 2011 , 21, 1329-38	14
976	MRI assessment of thoracic stent grafts after emergency implantation in multi trauma patients: a feasibility study. 2011 , 21, 1397-405	9
975	[Magnetic resonance imaging in rheumatology]. 2011 , 70, 493-506	0
974	The role of phosphate on Omniscan(®) dechelation: an in vitro relaxivity study at pH 7. 2011 , 24, 759-68	17
973	Nephrogene systemische Fibrose (NSF): Wie hoch ist das Risiko und wie können wir es vermeiden?. 2011 , 16, 462-468	
972	Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. 2011 , 38, 23-36	76

971	Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. 2011 , 41, 1401-6	23
970	Comparison of half-dose and full-dose gadolinium MR contrast on the enhancement of bone and soft tissue tumors. 2011 , 40, 327-33	5
969	Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury. 2011 , 144, 621-35	34
968	Assessing renal function with a rapid, handy, point-of-care whole blood creatinine meter before using contrast materials. 2011 , 29, 187-93	10
967	Assessment of renal impairment by non-contrast-enhanced conventional magnetic resonance imaging: comparison with ^{99m}Tc -DTPA renography. 2011 , 29, 378-85	6
966	Renal imaging in patients with renal impairment. 2011 , 12, 24-33	7
965	Early detection and intervention using neutrophil gelatinase-associated lipocalin (NGAL) may improve renal outcome of acute contrast media induced nephropathy: a randomized controlled trial in patients undergoing intra-arterial angiography (ANTI-CIN Study). 2011 , 12, 39	19
964	Nonenhanced methods for lower-extremity MRA: a phantom study examining the effects of stenosis and pathologic flow waveforms at 1.5T. 2011 , 33, 401-8	16
963	Unenhanced ECG-gated fast spin-echo MR digital subtraction angiography (MRDSA) using short echo-spacing three-dimensional sequence of femoral arteries: initial experience. 2011 , 34, 157-64	5
962	Use of respiratory biofeedback and CLAWS for increased navigator efficiency for imaging the thoracic aorta. 2011 , 66, 1666-73	11
961	MRI of stroke using hyperpolarized ^{129}Xe . 2011 , 24, 170-5	40
960	Impact of contrast enhanced MRI on lymphocyte DNA damage and serum visfatin level. 2011 , 44, 975-9	28
959	The feasibility of in vivo detection of gadolinium by prompt gamma neutron activation analysis following gadolinium-based contrast-enhanced MRI. 2011 , 69, 105-11	15
958	Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 3616-26	4-3 72
957	Breast MRI using a high-relaxivity contrast agent: an overview. 2011 , 196, 942-55	22
956	Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations. 2011 , 196, 545-52	23
955	Pulmonary functional imaging: qualitative comparison of Fourier decomposition MR imaging with SPECT/CT in porcine lung. 2011 , 260, 551-9	85
954	Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. 2011 , 260, 105-11	119

953	Unenhanced MR angiography: techniques and clinical applications in patients with chronic kidney disease. 2011 , 31, E13-33		76
952	Risk of nephrogenic systemic fibrosis in liver transplantation patients. 2011 , 197, 658-62		20
951	Peripheral arterial disease: the evolving role of non-invasive imaging. 2011 , 87, 189-98		27
950	Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients. 2011 , 259, 109-16		27
949	Nonenhanced MR angiography of the hand with flow-sensitive dephasing-prepared balanced SSFP sequence: initial experience with systemic sclerosis. 2011 , 259, 248-56		31
948	Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis. 2011 , 129, 661-3		14
947	Cryoglobulinaemia and rapidly deteriorating renal function in chronic lymphocytic leukaemia. <i>Nephrology Dialysis Transplantation</i> , 2011 , 26, 1101-3	4-3	3
946	Kidney function: glomerular filtration rate measurement with MR renography in patients with cirrhosis. 2011 , 259, 462-70		52
945	Carotid MRI: a tool for monitoring individual response to cardiovascular therapy?. 2011 , 9, 63-80		16
944	Nephrogenic systemic fibrosis. 2011 , 2, 51-6		5
943	Imaging in encapsulating peritoneal sclerosis. 2011 , 4, 281-4		7
942	Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment. 2011 , 33, 758-64		20
941	Ultraschalldiagnostik 2012. 2012 , 101, 1141-1142		
940	Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden. 2012 , 46, 48-53		13
939	Understanding nephrogenic systemic fibrosis. 2012 , 2012, 912189		23
938	Six years after. 2012 , 53, 827-9		9
937	Clinical outcomes in patients with renal artery stenosis treated with stent placement with embolic protection compared with those treated with stent alone. 2012 , 46, 447-54		7
936	Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. 2012 , 189, 318-27		42

935	[Renal toxicity of contrast agents in oncologic patients]. 2012 , 99, 295-307	8
934	[Cartilage regeneration]. 2012 , 150, e121-41; quiz e142	1
933	Immediate hypersensitivity reaction to gadolinium-based MR contrast media. 2012 , 264, 414-22	177
932	Unenhanced MR angiography of renal arteries: 51 patients. 2012 , 199, W629-37	17
931	Gadolinium accumulation and fibrosis in the liver after administration of gadoxetate disodium in a rat model of active hepatic fibrosis. 2012 , 264, 423-7	8
930	MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. 2012 , 33, 803-17	68
929	Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. 2012 , 263, 107-16	29
928	Nephrogenic systemic fibrosis. 2012 , 199, W17-23	84
927	Evaluation of renal artery in hypertensive patients by unenhanced MR angiography using spatial labeling with multiple inversion pulses sequence and by CT angiography. 2012 , 199, 1142-8	13
926	Non-contrast-enhanced magnetic resonance angiography: techniques and applications. 2012 , 10, 75-88	7
925	Pentoxifylline use in dermatology. 2012 , 11, 422-32	7
924	Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. 2012 , 5, 82-88	67
923	USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. 2012 , 265, 584-90	43
922	Nephrogenic systemic fibrosis in the podiatric patient. 2012 , 102, 419-21	3
921	MRI Safety. 2012 , 39-46	2
920	Development of manganese-based nanoparticles as contrast probes for magnetic resonance imaging. 2012 , 2, 45-54	104
919	Macromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential?. 2012 , 45, 8939-8952	41
918	Dissociation kinetics of open-chain and macrocyclic gadolinium(III)-aminopolycarboxylate complexes related to magnetic resonance imaging: catalytic effect of endogenous ligands. 2012 , 18, 16426-35	81

917	Endovascular management of acute limb ischemia. 2012 , 26, 110-24	22
916	Imaging for luminal disease and complications: CT enterography, MR enterography, small-bowel follow-through, and ultrasound. 2012 , 41, 497-512	25
915	Safety of older generations of gadolinium in mild-to-moderate renal failure. 2012 , 34, 176-80	5
914	Contrast-enhanced peripheral MRA: technique and contrast agents. 2012 , 53, 769-77	21
913	Organic radical contrast agents for magnetic resonance imaging. 2012 , 134, 15724-7	129
912	Prospective intraindividual comparison of unenhanced magnetic resonance imaging vs contrast-enhanced computed tomography for the planning of endovascular abdominal aortic aneurysm repair. 2012 , 55, 679-87	10
911	Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. 2012 , 81, 885-90	27
910	Nonenhanced ECG-gated time-resolved 4D steady-state free precession (SSFP) MR angiography (MRA) of cerebral arteries: comparison at 1.5T and 3T. 2012 , 81, e531-5	9
909	Hydrogels Incorporating GdDOTA: Towards Highly Efficient Dual T1/T2 MRI Contrast Agents. 2012 , 124, 9253-9256	4
908	A comparison of 4D time-resolved MRA with keyhole and 3D time-of-flight MRA at 3.0 T for the evaluation of cerebral aneurysms. 2012 , 12, 50	11
907	Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. 2012 , 14, 18	21
906	Optimization of single shot 3D breath-hold non-enhanced MR angiography of the renal arteries. 2012 , 14, 30	5
905	Gadolinium in pediatric cardiovascular magnetic resonance: what we know and how we practice. 2012 , 14, 56	22
904	Cardiovascular magnetic resonance physics for clinicians: Part II. 2012 , 14, 66	62
903	Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis. 2012 , 121, c91-4	14
902	Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure. 2012 , 26, 489-503	65
901	Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent. 2012 , 33, 9225-31	15
900	In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. 2012 , 81, 2562-7	7

899	Pain in end-stage renal disease: a frequent and neglected clinical problem. 2012,	8
898	Insuffisance rñale chronique et dialyse. 2012, 213-223	
897	Contemporary imaging of the renal mass. 2012, 39, 161-70, vi	51
896	Arterial Imaging. 2012, 103-117	
895	Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function. 2012, 19, 1181-5	6
894	Target binding improves relaxivity in aptamer-gadolinium conjugates. 2012, 17, 1159-75	13
893	Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). 2012, 27, 1697-703	25
892	Advances in uroradiologic imaging in children. 2012, 50, 207-18, v	8
891	Speciation of Gd-based MRI contrast agents and potential products of transmetalation with iron ions or parenteral iron supplements. 2012, 404, 2133-41	32
890	Imaging in Clinical Trials. 2012, 597-617	
889	Changing trends in a decade of vascular radiology-the impact of technical developments of non-invasive techniques on vascular imaging. 2012, 3, 495-504	4
888	Nephrogenic systemic fibrosis: concepts and perspectives. 2012, 87, 597-607	12
887	Gadolinium-induced fibrosis testing by protein targeting assay and superparamagnetic iron oxide nanoparticle-based magnetic resonance microscopy of skin and kidneys. 2012, 4, 139-161	1
886	Non-contrast-enhanced MRI of the pulmonary blood volume using two-compartment-modeled T1-relaxation. 2012, 36, 397-404	10
885	New look at renal vasculature: 7 tesla nonenhanced T1-weighted FLASH imaging. 2012, 36, 714-21	19
884	MR angiography of carotid artery aneurysms in a porcine model at 3 Tesla: comparison of two different macrocyclic gadolinium chelates and of dynamic and conventional techniques. 2012, 36, 1203-12	2
883	Hydrogels incorporating GdDOTA: towards highly efficient dual T1/T2 MRI contrast agents. 2012, 51, 9119-22	117
882	Rare-Earth nanoparticles with enhanced upconversion emission and suppressed rare-Earth-ion leakage. 2012, 18, 5558-64	179

881	Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis. 2012 , 6, 97-105	8
880	Non-enhanced ECG-gated respiratory-triggered 3-D steady-state free-precession MR angiography with slab-selective inversion: initial experience in visualisation of renal arteries in free-breathing children without renal artery abnormality. 2012 , 42, 785-90	3
879	Arterial spin labelling: final steps to make it a clinical reality. 2012 , 25, 79-82	25
878	Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. 2012 , 165, 1151-62	18
877	Identification and quantification of potential metabolites of Gd-based contrast agents by electrochemistry/separations/mass spectrometry. 2012 , 1240, 147-55	30
876	Feasibility of non-contrast-enhanced magnetic resonance angiography for imaging upper extremity vasculature prior to vascular access creation. 2012 , 43, 88-94	28
875	Nephrogenic systemic fibrosis: a case report and review on Japanese patients. 2012 , 39, 449-53	5
874	Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. 2012 , 19, 806-11	21
873	Stimulation of fibroblast proliferation by insoluble gadolinium salts. 2012 , 145, 257-67	22
872	Dynamically applied B1+ shimming solutions for non-contrast enhanced renal angiography at 7.0 Tesla. 2013 , 69, 114-26	50
871	Prospective self-gated nonenhanced magnetic resonance angiography of the peripheral arteries. 2013 , 69, 158-62	11
870	Magnetic Resonance Imaging of the Bone Marrow Contrast Media for Bone Marrow Imaging. 2013 , 355-365	
869	Coupling fast water exchange to slow molecular tumbling in Gd ³⁺ chelates: why faster is not always better. 2013 , 52, 8436-50	27
868	3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. 2013 , 29, 1085-94	21
867	Metal-Based MRI Contrast Agents. 2013 , 901-932	1
866	Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd ³⁺ to the glycosaminoglycan heparin. 2013 , 8, 108-16	24
865	Chronic fibrosing conditions in abdominal imaging. 2013 , 33, 1053-80	38
864	Contrast alternatives for iodinated contrast allergy and renal dysfunction: options and limitations. 2013 , 57, 593-8	34

863	Preliminary experience with superparamagnetic iron oxide-enhanced dynamic magnetic resonance imaging and comparison with contrast-enhanced computed tomography in endoleak detection after endovascular aneurysm repair. 2013 , 58, 66-72	16
862	Single cell tracking of gadolinium labeled CD4+ T cells by laser ablation inductively coupled plasma mass spectrometry. 2013 , 85, 10627-34	54
861	Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening. 2013 , 24, 462001	60
860	ECG-triggered non-enhanced MR angiography of peripheral arteries in comparison to DSA in patients with peripheral artery occlusive disease. 2013 , 26, 271-80	19
859	MRI-visible poly(L-lactide) with controlled contrast agent ratios for enhanced visualization in temporary imaging applications. 2013 , 14, 3626-34	20
858	A theoretical study on magnetic properties of bis-TEMPO diradicals with possible application. 2013 , 1024, 15-23	12
857	Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure. 2013 , 40, 935-44	12
856	Quantitative mouse renal perfusion using arterial spin labeling. 2013 , 26, 1225-32	26
855	Noninvasive visualization of endoleaks after endovascular aortic aneurysm repair through unenhanced MRI with motion-sensitized driven equilibrium preparation: Phantom experiments. 2013 , 38, 714-21	2
854	Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. 2013 , 23, 307-18	329
853	Lanthanide(III) complexes of some natural siderophores: a thermodynamic, kinetic and relaxometric study. 2013 , 127, 53-61	8
852	Simultaneous magnetic resonance angiography and perfusion (MRAP) measurement: initial application in lower extremity skeletal muscle. 2013 , 38, 1237-44	18
851	MRI-detectable nanoparticles: the potential role in the diagnosis of and therapy for chronic kidney disease. 2013 , 20, 479-87	7
850	Non-contrast enhanced magnetic resonance angiography techniques in candidates for kidney transplantation: A comparative study. 2013 , 19, 212-217	1
849	Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. 2013 , 183, 796-807	13
848	Arterial Spin Labeling Magnetic Resonance Imaging: Intracranial and Emerging Extracranial Applications. 2013 , 8, 295-309	1
847	Evaluation of renal blood flow using multi-phase echo-planar magnetic resonance imaging and signal targeting with alternating radiofrequency (EPISTAR) in 3-T magnetic resonance imaging. 2013 , 6, 86-91	3
846	Quantitative parametric MRI of articular cartilage: a review of progress and open challenges. 2013 , 86, 20120163	56

845	Is macrocycle a synonym for kinetic inertness in Gd(III) Complexes? Effect of coordinating and noncoordinating substituents on inertness and relaxivity of Gd(III) chelates with DO3A-like ligands. 2013 , 52, 4084-96	41
844	Stability and Toxicity of Contrast Agents. 2013 , 157-208	31
843	Perfusion MRI: the five most frequently asked technical questions. 2013 , 200, 24-34	225
842	Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review. 2013 , 764, 1-16	84
841	Introductory Chemistry: A Molar Relaxivity Experiment in the High School Classroom. 2013 , 90, 922-925	5
840	Intracellular aggregation of multimodal silica nanoparticles for ultrasound-guided stem cell implantation. 2013 , 5, 177ra35	77
839	Cardiovascular Magnetic Resonance and Multidetector Computed Tomography. 2013 , 221-248	
838	Contrast-enhanced magnetic resonance angiography of the peripheral arteries: technique, tips, pitfalls and problems. 2013 , 57, 125-40	3
837	Objective evaluation of acute adverse events and image quality of gadolinium-based contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation. Pilot study. 2013 , 31, 96-101	9
836	Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. 2013 , 31, 139-44	8
835	Patient Information. 2013 , 64-85	
834	Contrast-enhanced MR imaging of hand and finger joints in patients with early rheumatoid arthritis: do we really need a full dose of gadobenate dimeglumine for assessing synovial enhancement at 3 T?. 2013 , 268, 161-9	12
833	Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. 2013 , 266, 773-82	41
832	Comparison of nonenhanced MR angiographic subtraction techniques for infraglenoid arteries at 1.5 T: a preliminary study. 2013 , 267, 293-304	24
831	Prediction and assessment of responses to renal artery revascularization with dynamic contrast-enhanced magnetic resonance imaging: a pilot study. 2013 , 305, F672-8	32
830	Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. 2013 , 131, 259-70	18
829	A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent. 2013 , 48, 745-54	16
828	Renal artery stenosis - an update. 2013 , 125, 43-50	3

827	A dual-modal magnetic nanoparticle probe for preoperative and intraoperative mapping of sentinel lymph nodes by magnetic resonance and near infrared fluorescence imaging. 2013 , 28, 100-11	27
826	Continuous magnetic resonance perfusion imaging acquisition during systemic thrombolysis in acute stroke. 2013 , 35, 554-9	12
825	Validation of a screening instrument for nephrogenic systemic fibrosis. 2013 , 65, 637-42	2
824	Functional MRI of the kidneys. 2013 , 37, 282-93	59
823	2012 ISMRM Lauterbur Lecture. MRI: from science to society. 2013 , 37, 753-60	4
822	Thursday 17th October 2013. 2013 , 57, 1-44	
821	Focal liver lesion classification and characterization in noncirrhotic liver: a prospective comparison of diffusion-weighted magnetic resonance-related parameters. 2013 , 37, 560-7	12
820	Surgery in the patient with renal disease. 299-330	
819	Direct portal vein thrombosis visualization with t2*-weighted magnetic resonance imaging. 2013 , 10, 1570-4	3
818	Diffusion-weighted imaging of the liver: an update. 2013 , 13, 171-85	23
817	Diagnostic accuracy of computer tomography angiography and magnetic resonance angiography in the stenosis detection of autologous hemodialysis access: a meta-analysis. 2013 , 8, e78409	7
816	Dynamic susceptibility contrast MRI: acquisition and analysis techniques. 16-37	1
815	Imaging in Kidney Transplantation. 2013 ,	3
814	Safety of gadopentetate dimeglumine after 120 million administrations over 25 years of clinical use. 2013 , 12, 297-304	40
813	Mapping of autogenous saphenous veins as an imaging adjunct to peripheral MR angiography in patients with peripheral arterial occlusive disease and peripheral bypass grafting: prospective comparison with ultrasound and intraoperative findings. 2014 , 9, e112340	0
812	[Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis]. 2014 , 142, 1565-74	2
811	Value of the diffusion-weighted MRI in the differential diagnostics of malignant and benign kidney neoplasms - our clinical experience. 2014 , 79, 290-5	23
810	Gadolinium detection via in vivo prompt gamma neutron activation analysis following gadolinium-based contrast agent injection: a pilot study in 10 human participants. 2014 , 35, 1861-72	9

809	Multi-Modality Atherosclerosis Imaging and Diagnosis. 2014,		13
808	Hexameric Mn(II) dendrimer as MRI contrast agent. 2014, 20, 14507-13		44
807	Pharmacovigilance: When to Report Adverse Reactions to Contrast Media. 2014, 29-31		
806	Vascular imaging: the evolving role of the multidisciplinary team meeting in peripheral vascular disease. 2014, 31, 320-9		2
805	How safe is renal replacement therapy? A national study of mortality and adverse events contributing to the death of renal replacement therapy recipients. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 681-7	4-3	21
804	Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis. 2014, 186, 661-9		47
803	Design of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers. 2014, 34, 1070-99		22
802	Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report. 2014, 87, 20140307		22
801	Pregnancy and Lactation: Intravascular Use of Contrast Media. 2014, 113-120		1
800	Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. 2014, 175, 113-25		23
799	Retrospective assessment of the utility of an iron-based agent for contrast-enhanced magnetic resonance venography in patients with endstage renal diseases. 2014, 40, 113-8		39
798	A study on the synthesis and properties of substituted EHBG-Fe(III) complexes as potential MRI contrast agents. 2014, 769, 100-105		9
797	Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Media. 2014, 207-217		5
796	Theranostic MRI: the future for Type 1 diabetes management?. 2014, 6, 25-39		4
795	Renal Vascular Disease. 2014,		1
794	Renal MR Angiography. 2014, 247-258		
793	Imaging management of incidentally detected small renal masses. 2014, 31, 9-19		37
792	Nephrogenic systemic fibrosis risk and liver disease. 2014, 2014, 679605		5

791	Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephroghique Systfrique study. 2014 , 49, 109-15	52
790	Magnetic resonance imaging in ESRD patients: what are the options?. 2014 , 27, 610-3	
789	Skin Manifestations in Rheumatic Disease. 2014 ,	6
788	Kidney Transplantation. 2014 ,	2
787	Hemodynamic analysis of renal artery stenosis using computational fluid dynamics technology based on unenhanced steady-state free precession magnetic resonance angiography: preliminary results. 2014 , 30, 367-75	8
786	Pediatric nephrogenic systemic fibrosis is rarely reported: a RADAR report. 2014 , 44, 173-80	60
785	Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. 2014 , 19, 259-70	18
784	Gadolinium and nephrogenic systemic fibrosis: an update. 2014 , 29, 1927-37	55
783	Techniques in Cartilage Repair Surgery. 2014 ,	3
782	Gadolinium-containing endohedral fullerenes: structures and function as magnetic resonance imaging (MRI) agents. 2014 , 43, 7346-58	69
781	Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. 2014 , 65, 96-105	105
780	Contrast agents for MRI: 30+ years and where are we going?. 2014 , 19, 127-31	109
779	Technical aspects of bile duct evaluation and exploration. 2014 , 94, 281-96	12
778	Neurologic complications of myocardial infarction. 2014 , 119, 93-110	1
777	Contrast Media. 2014 ,	17
776	Assessment of perfusion deficits in ischemic stroke using 3D-GRASE arterial spin labeling magnetic resonance imaging with multiple inflow times. 2014 , 24, 453-9	14
775	Role of endothelin-1/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis. 2014 , 23, 664-9	8
774	The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. 2014 , 44, 895-913	79

773	[Gadolinium-based contrast agents for magnetic resonance imaging]. 2014 , 56 Suppl 1, 21-8	7
772	Nanoassemblies of Gd-DTPA-monooleyl and glycerol monooleate amphiphiles as potential MRI contrast agents. 2014 , 2, 1225-1233	21
771	Tetraphosphonated thiophene ligand: mixing the soft and the hard. 2014 , 43, 9070-80	7
770	Substitution of gadolinium ethylenediaminetetraacetate with phosphites: towards gadolinium deposit in nephrogenic systemic fibrosis. 2014 , 43, 639-45	12
769	Clinical imaging in regenerative medicine. 2014 , 32, 804-18	175
768	Elemental and chemically specific X-ray fluorescence imaging of biological systems. 2014 , 114, 8499-541	183
767	New magnetic resonance imaging methods in nephrology. 2014 , 85, 768-78	71
766	In vitro toxicity in long-term cell culture of MR contrast agents targeted to cartilage evaluation. 2014 , 22, 1337-45	6
765	Gadolinium- or iodine-based contrast media: which choice?. 2014 , 55, 771-5	5
764	Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus. 2014 , 14, 1551-8	124
763	CAIPIRINHA-Dixon-TWIST (CDT)-volume-interpolated breath-hold examination (VIBE) for dynamic liver imaging: comparison of gadoterate meglumine, gadobutrol and gadoxetic acid. 2014 , 83, 2007-12	25
762	Determination of location, size, and transmuralty of chronic myocardial infarction without exogenous contrast media by using cardiac magnetic resonance imaging at 3 T. 2014 , 7, 471-81	41
761	MR Contrast Agent Safety in the Age of Nephrogenic Systemic Fibrosis: Update 2014. 2014 , 2, 1	
760	Myocardial viability: it is still alive. 2014 , 44, 358-74	20
759	Gadolinium promoted proliferation in mouse embryo fibroblast NIH3T3 cells through Rac and PI3K/Akt signaling pathways. 2014 , 27, 753-62	12
758	Preliminary experience of a new perspective view technology for the detection of portal vein thrombus in hepatocellular carcinoma patients. 2014 , 39, 1145-52	2
757	An overview of magnetic resonance enterography for Crohn's disease. 2014 , 59, 2040-9	3
756	Fe 3+ ions anchored to Fe@O-MWCNTs as double impact T 2 MRI contrast agents. 2014 , 136, 34-36	7

755	Current status of nephrogenic systemic fibrosis. 2014 , 69, 661-8	79
754	A practical guide to magnetic resonance vascular imaging: techniques and applications. 2014 , 28, 1052-61	9
753	Paradigms and challenges for bioapplication of rare earth upconversion luminescent nanoparticles: small size and tunable emission/excitation spectra. 2014 , 47, 1001-9	287
752	Magnetic resonance contrast agents for liver imaging. 2014 , 22, 283-93	12
751	Magnetic resonance imaging characterization of microbial infections. 2014 , 93, 136-46	16
750	Gadolinium deposits could influence the course of encapsulating peritoneal sclerosis. 2014 , 34, 561-5	1
749	Renal perfusion imaging with two-dimensional navigator gated arterial spin labeling. 2014 , 71, 570-9	32
748	Unenhanced respiratory-gated magnetic resonance angiography (MRA) of renal artery in hypertensive patients using true fast imaging with steady-state precession technique compared with contrast-enhanced MRA. 2014 , 38, 700-4	5
747	Hyperpolarized H ₂ O MR angiography. 2014 , 71, 50-6	26
746	MRI in pediatric neck abscesses. 2015 , 02, 307-312	
745	Contrast agents. 2015 , 1425-1442	
744	Porous silicon nanoparticles as biocompatible contrast agents for magnetic resonance imaging. 2015 , 107, 233702	34
743	T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents. 2015 , 50, 473-80	185
742	Gefdiagnostik bei reduzierter Nierenfunktion. 2015 , 20, 451-454	
741	Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. 2015 , 41, 1259-67	18
740	Implementation of a comprehensive MR safety course for medical students. 2015 , 42, 1478-86	6
739	Commentary on T1-Weighted Hypersignal in the Deep Cerebellar Nuclei After Repeated Administrations of Gadolinium-Based Contrast Agents in Healthy Rats: Difference Between Linear and Macrocyclic Agents. 2015 , 50, 481-2	25
738	Practice advisory on anesthetic care for magnetic resonance imaging: an updated report by the american society of anesthesiologists task force on anesthetic care for magnetic resonance imaging. 2015 , 122, 495-520	44

737	Emerging applications for ferumoxytol as a contrast agent in MRI. 2015 , 41, 884-98	250
736	Quantitative contrast-enhanced MRI with superparamagnetic nanoparticles using ultrashort time-to-echo pulse sequences. 2015 , 74, 431-41	28
735	Contrast Media for X-ray and Magnetic Resonance Imaging: Development, Current Status and Future Perspectives. 2015 , 50, 671-8	17
734	Gadolinium deposition in the brain: another concern regarding gadolinium-based contrast agents. 2015 , 21, 269-70	16
733	The feasibility of in vivo quantification of bone-gadolinium in humans by prompt gamma neutron activation analysis (PGNAA) following gadolinium-based contrast-enhanced MRI. 2015 , 116, 248-251	2
732	Diagnostic agents. 2015 , 527-540	1
731	Contrast media, radionuclides and diagnostics. 2015 , 813-819	
730	Advances and perspectives in nanoprobes for noninvasive lymph node mapping. 2015 , 10, 1019-36	23
729	Current tools for prediction of arteriovenous fistula outcomes. 2015 , 8, 282-9	33
728	Luminescent lanthanide nanomaterials: an emerging tool for theranostic applications. 2015 , 10, 1477-91	30
727	Photoacoustic tomography of the human finger: towards the assessment of inflammatory joint diseases. 2015 ,	2
726	Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study. 2015 , 50, 416-22	39
725	Nephrogenic Systemic Fibrosis on Mammography. 2015 , 44, 517-20	2
724	Non-clinical safety assessment of gadoterate meglumine (Dotarem(®)) in neonatal and juvenile rats. 2015 , 73, 960-70	12
723	Cardiac imaging in patients with chronic kidney disease. 2015 , 11, 207-20	23
722	Facile preparation of doxorubicin-loaded upconversion@polydopamine nanoplateforms for simultaneous in vivo multimodality imaging and chemophotothermal synergistic therapy. 2015 , 4, 559-68	134
721	Half-dose gadoxetic acid-enhanced liver magnetic resonance imaging in patients at risk for nephrogenic systemic fibrosis. 2015 , 84, 378-383	11
720	Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?. 2015 , 88, 20140526	13

719	The role of equilibrium and kinetic properties in the dissociation of Gd[DTPA-bis(methylamide)] (Omniscan) at near to physiological conditions. 2015 , 21, 4789-99	34
718	Thermodynamic stability, kinetic inertness and relaxometric properties of monoamide derivatives of lanthanide(III) DOTA complexes. 2015 , 44, 5467-78	32
717	High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. 2015 , 30, 515-21	43
716	Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation. 2015 , 72, 46-56	11
715	TiO ₂ nanoparticles functionalized monolithic capillary microextraction online coupled with inductively coupled plasma mass spectrometry for the analysis of Gd ion and Gd-based contrast agents in human urine. 2015 , 87, 8949-56	34
714	Dermatological Manifestations of Kidney Disease. 2015 ,	
713	Update on systemic sclerosis. 2015 , 15, 25	8
712	Facile synthesis of NaGdF ₄ :Yb/Er@CaF ₂ nanoparticles with enhanced upconversion fluorescence and stability via a sequential growth process. 2015 , 17, 5900-5905	12
711	Vasa vasorum in atherosclerosis and clinical significance. 2015 , 16, 11574-608	78
710	Preoperative planning of renal transplantation: a comparison of non-contrast-enhanced ultrasonography, computed tomography, and magnetic resonance angiography with observations from surgery. 2015 , 56, 1527-33	3
709	Noncontrast magnetic resonance angiography: concepts and clinical applications. 2015 , 53, 457-76	18
708	Activatable Dendritic F Probes for Enzyme Detection. 2015 , 4, 422-425	20
707	Atherosclerotic neovasculature MR imaging with mixed manganese-gadolinium nanocolloids in hyperlipidemic rabbits. 2015 , 11, 569-78	7
706	ACR Appropriateness Criteria indeterminate renal mass. 2015 , 12, 333-41	53
705	[Physico-chemical and toxicological profile of gadolinium chelates as contrast agents for magnetic resonance imaging]. 2015 , 73, 266-76	6
704	Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers. 2015 , 11, 601-9	8
703	The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken. 2015 , 25, 745-50	5
702	Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?. 2015 , 276, 741-7	38

701	Residual or retained gadolinium: practical implications for radiologists and our patients. 2015 , 275, 630-4	189
700	Fe(III) salEen derived Schiff base complexes as potential contrast agents. 2015 , 432, 258-266	9
699	Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. 2015 , 275, 772-82	917
698	Dissolution of upconverting fluoride nanoparticles in aqueous suspensions. 2015 , 5, 27393-27397	37
697	Safety of MRI and CT. 2015 , 63-72	
696	Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis. 2015 , 24, 57-65	17
695	Virus-based nanomaterials as positron emission tomography and magnetic resonance contrast agents: from technology development to translational medicine. 2015 , 7, 708-21	34
694	Revisiting the risks of MRI with Gadolinium based contrast agents-review of literature and guidelines. 2015 , 6, 553-8	124
693	[60 years hemo- and peritoneal dialysis, 50 years kidney transplantation, 25 years immunoapheresis in Austria]. 2015 , 127 Suppl 2, S69-113	1
692	Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies. 2015 , 45, 1831-41	13
691	Surveillance Imaging Following Endovascular Aneurysm Repair. 2015 , 32, 239-48	22
690	Safe Use of Contrast Media: What the Radiologist Needs to Know. 2015 , 35, 1738-50	161
689	A Practical Guide to MR Imaging Safety: What Radiologists Need to Know. 2015 , 35, 1722-37	75
688	The gadolinium-based contrast agent Omniscan [®] promotes in vitro fibroblast survival through in situ precipitation. 2015 , 7, 1103-10	3
687	Native T1 Mapping by 3-T CMR Imaging for Characterization of Chronic Myocardial Infarctions. 2015 , 8, 1019-1030	64
686	Native T1 Mapping for Myocardial Infarction: Time to Throw Out the Gadolinium?. 2015 , 8, 1031-1033	4
685	Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study. 2015 , 205, 533-9	3
684	Vascular Imaging With Ferumoxytol as a Contrast Agent. 2015 , 205, W366-73	89

683	Aliphatic polyesters for medical imaging and theranostic applications. 2015 , 97, 350-70	46
682	Basic Principles of Cardiovascular MRI. 2015 ,	3
681	A Manganese Alternative to Gadolinium for MRI Contrast. 2015 , 137, 15548-57	175
680	Quantitative and qualitative comparison of 0.025 mmol/kg gadobenate dimeglumine for abdominal MRI at 1.5T and 3T MRI in patients with low estimated glomerular filtration rate. 2015 , 84, 26-32	6
679	Ferumoxitol-enhanced magnetic resonance angiography is a feasible method for the clinical evaluation of lower extremity arterial disease. 2015 , 29, 63-8	19
678	Trace Elements in Patients with Chronic Kidney Disease. 2015 , 429-439	1
677	Four-dimensional flow magnetic resonance imaging in cirrhosis. 2016 , 22, 89-102	18
676	Diagnostic Accuracy of Three Different Protocols for 3.0T Coronary Magnetic Resonance Angiography. 2016 , 57, 535-40	
675	Blood pool contrast agents for venous magnetic resonance imaging. 2016 , 6, 508-518	18
674	Importance of Measuring Lanthanides. 2016 , 59-82	
673	Value of diffusion-weighted MRI in evaluation of solid hepatic focal lesions in patients with renal insufficiency. 2016 , 47, 1265-1274	
672	A transferrin-target magnetic/fluorescent dual-mode probe significantly enhances the diagnosis of non-small cell lung cancer. 2016 , 7, 40047-40059	11
671	Click Stimulus Electrocochleography Versus MRI With Intratympanic Contrast in Ménière's Disease: A Systematic Review. 2016 , 37, 421-7	13
670	Left atrial strain: A useful index in atrial fibrillation. 2016 , 220, 208-13	64
669	Time-of-Flight Magnetic Resonance Angiography With Sparse Undersampling and Iterative Reconstruction: Comparison With Conventional Parallel Imaging for Accelerated Imaging. 2016 , 51, 372-8	23
668	Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion. 2016 , 51, 691-700	67
667	Measurement of glomerular filtration rate by dynamic contrast-enhanced magnetic resonance imaging using a subject-specific two-compartment model. 2016 , 4, e12755	9
666	Optimization of saturation-recovery dynamic contrast-enhanced MRI acquisition protocol: monte carlo simulation approach demonstrated with gadolinium MR renography. 2016 , 29, 969-77	2

665	Chronic, dusky, indurated plaques on the legs of a 31-year-old woman. 2016 , 41, 328-30	2
664	Optimized 4D time-of-flight MR angiography using saturation pulse. 2016 , 43, 1320-6	2
663	Pathophysiology of gadolinium-associated systemic fibrosis. 2016 , 311, F1-F11	40
662	Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry. 2016 , 37, 959-72	19
661	The study of in vivo X-ray fluorescence (XRF) technique for gadolinium (Gd) measurements in human bone. 2016 , 11, T08001-T08001	1
660	Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab. 2016 , 13, 23	4
659	Preventing Allergic Reactions to Gadolinium-Based Contrast Agents. 2016 , 25, 275-279	9
658	A phantom-based feasibility study for detection of gadolinium in bone in-vivo using X-ray fluorescence. 2016 , 112, 103-9	11
657	Gadolinium in Humans: A Family of Disorders. 2016 , 207, 229-33	73
656	Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. 2016 , 29, 365-76	402
655	Performance of DWI as a Rapid Unenhanced Technique for Detecting Mammographically Occult Breast Cancer in Elevated-Risk Women With Dense Breasts. 2016 , 207, 205-16	54
654	Alzheimer's disease: The use of contrast agents for magnetic resonance imaging to detect amyloid beta peptide inside the brain. 2016 , 327-328, 27-34	19
653	Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 1. 2016 , 57, 515-20	25
652	MR Safety Update 2015: Where Do the Risks Come From?. 2016 , 4, 1	9
651	Gadolinium Deposition in Humans: When Did We Learn That Gadolinium Was Deposited In Vivo?. 2016 , 51, 236-40	41
650	Considerations for Imaging the Inferior Vena Cava (IVC) with/without IVC Filters. 2016 , 33, 109-21	3
649	Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience. 2016 , 34, 1341-1345	51
648	Synthesis and Relaxometric Characterization of a New Mn(II)-EDTA-Deoxycholic Acid Conjugate Complex as a Potential MRI Blood Pool Agent. 2016 , 1, 1607-1612	4

647	EDTA capped iron oxide nanoparticles magnetic micelles: drug delivery vehicle for treatment of chronic myeloid leukemia and T1- and T2 dual contrast agent for magnetic resonance imaging. 2016 , 40, 9507-9519 ¹²	
646	Gadolinium toxicity and treatment. 2016 , 34, 1394-1398	70
645	Noncontrast Magnetic Resonance Angiography Using Inflow Sensitive Inversion Recovery Technique for Vascular Evaluation in Pre-liver Transplantation Recipients. 2016 , 48, 1032-5	4
644	De Novo Designed Imaging Agents Based on Lanthanide Peptides Complexes. 2016 , 580, 557-80	5
643	Transient versus Static Electron Spin Relaxation in Mn(2+) Complexes Relevant as MRI Contrast Agents. 2016 , 120, 6467-76	14
642	Physico-chemical properties of Mn complexes formed with cis- and trans-DO2A: thermodynamic, electrochemical and kinetic studies. 2016 , 163, 206-213	21
641	High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification. 2016 , 11, 245-50	23
640	Contrast induced nephropathy in vascular surgery. 2016 , 117 Suppl 2, ii63-ii73	14
639	Gadolinium toxicity: Iron and ferroportin as central targets. 2016 , 34, 1373-1376	32
638	Gadolinium deposition disease: Initial description of a disease that has been around for a while. 2016 , 34, 1383-1390	85
637	Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities. 2016 , 1, 17-28	1
636	Abnormal Grey Matter Arteriolar Cerebral Blood Volume in Schizophrenia Measured With 3D Inflow-Based Vascular-Space-Occupancy MRI at 7T. 2017 , 43, 620-632	23
635	Detonation Nanodiamonds. 2016 , 525-540	1
634	Fascitis de Shulman. 2016 , 49, 1-8	
633	The application of T2W SPIR-FLAIR in the diagnosis of hip synovitis in patients with spondyloarthritis. 2016 , 89, 20160566	1
632	Delayed gadolinium-enhanced MRI of meniscus (dGEMRIM) and cartilage (dGEMRIC) in healthy knees and in knees with different stages of meniscus pathology. 2016 , 17, 406	6
631	Adverse Effects of Gadolinium-Based Contrast Agents: Changes in Practice Patterns. 2016 , 25, 163-9	14
630	Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases. 2016 , 51, 661-5	53

629	Role of Contrast in MR Imaging. 2016 , 25, 151-6	2
628	Ultra-fast Steady-State Free Precession Pulse Sequence for Fourier Decomposition Pulmonary MRI. 2016 , 75, 1647-53	22
627	Measurement of arteriolar blood volume in brain tumors using MRI without exogenous contrast agent administration at 7T. 2016 , 44, 1244-1255	11
626	Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. 2016 , 51, 701-705	36
625	Engineered atherosclerosis-specific zinc ferrite nanocomplex-based MRI contrast agents. 2016 , 14, 6	14
624	Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. 2016 , 46, 1332-40	23
623	Gadolinium(III) based nanoparticles for T1-weighted magnetic resonance imaging probes. 2016 , 6, 60945-60966	2
622	Magnetic Resonance Contrast Agents for Neuroradiology. 2016 , 183-192	
621	Systemic Sclerodermas. 2016 , 384-405.e9	0
620	Gadolinium-based contrast agents: did we miss something in the last 25 years?. 2016 , 121, 478-81	17
619	A preliminary report of breast cancer screening by positron emission mammography. 2016 , 30, 130-7	26
618	Brain gadolinium deposition after administration of gadolinium-based contrast agents. 2016 , 34, 3-9	113
617	Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function. 2016 , 51, 447-53	292
616	Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update. 2016 , 37, 1192-8	260
615	Application of intravoxel incoherent motion perfusion imaging to shoulder muscles after a lift-off test of varying duration. 2016 , 29, 66-73	22
614	Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus. 2016 , 51, 273-9	101
613	Imaging patients with renal impairment. 2016 , 41, 1108-21	2
612	25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. 2016 , 33, 1-28	211

611	Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. 2016 , 58, 433-41	98
610	T1 hyperintensity in the brain after multiple intravenous injections of gadolinium-based contrast agents. 2016 , 57, 389-91	9
609	Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent. 2016 , 61, 659-64	15
608	Gadolinium-Induced Fibrosis. 2016 , 67, 273-91	48
607	Interaction of Gd-DTPA with phosphate and phosphite: toward the reaction intermediate in nephrogenic systemic fibrosis. 2016 , 45, 5388-94	6
606	Magnetic resonance safety. 2016 , 41, 444-51	72
605	Cytotoxic interactions of bare and coated NaGdF ₄ :Yb(3+):Er(3+) nanoparticles with macrophage and fibroblast cells. 2016 , 32, 16-25	29
604	Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. 2016 , 98, 113-33	70
603	Imaging of atherosclerosis. 2016 , 32, 5-12	14
602	Endoleak detection after endovascular aneurysm repair using unenhanced MRI with flow suppression technique: Feasibility study in comparison with contrast-enhanced CT. 2017 , 27, 336-344	5
601	Effects of exposure to gadolinium on the development of geographically and phylogenetically distant sea urchins species. 2017 , 128, 98-106	35
600	Intravenous injection of gadobutrol in an epidemiological study group did not lead to a difference in relative signal intensities of certain brain structures after 5 years. 2017 , 27, 772-777	31
599	Research cardiac magnetic resonance imaging in end stage renal disease - incidence, significance and implications of unexpected incidental findings. 2017 , 27, 315-324	5
598	Matrix pencil decomposition of time-resolved proton MRI for robust and improved assessment of pulmonary ventilation and perfusion. 2017 , 77, 336-342	30
597	Gadolinium deposition in the brain: association with various GBCAs using a generalized additive model. 2017 , 27, 3353-3361	26
596	Gd-DTPA-induced dynamic metabonomic changes in rat biofluids. 2017 , 44, 15-25	2
595	Development of the application of speciation in chemistry. 2017 , 352, 401-423	33
594	Systemic Fibroinflammatory Disorders. 2017 ,	1

593	One-Component Supramolecular Filament Hydrogels as Theranostic Label-Free Magnetic Resonance Imaging Agents. 2017 , 11, 797-805	72
592	Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract. 2017 , 70, 1072-1078	27
591	Four-dimensional phase-contrast vastly undersampled isotropic projection reconstruction (4D PC-VIPR) MR evaluation of the renal arteries in transplant recipients: Preliminary results. 2017 , 46, 595-603	11
590	Gadolinium-based contrast agents: A comprehensive risk assessment. 2017 , 46, 338-353	188
589	[Optimized detection and characterization of liver metastases : The role of current MRI contrast agents]. 2017 , 57, 373-381	1
588	Magnetic resonance imaging of the liver, biliary tract, and pancreas. 2017 , 358-377.e2	1
587	Updates on MRI Evaluation of Pediatric Large Airways. 2017 , 208, 971-981	14
586	Shape memory polymers with enhanced visibility for magnetic resonance- and X-ray imaging modalities. 2017 , 54, 45-57	15
585	Contemporary Imaging of Cerebral Arteriovenous Malformations. 2017 , 208, 1320-1330	26
584	Self-Assembled, Biodegradable Magnetic Resonance Imaging Agents: Organic Radical-Functionalized Diblock Copolymers. 2017 , 6, 176-180	29
583	Gadolinium released by the linear gadolinium-based contrast-agent Gd-DTPA decreases the activity of human epithelial Na channels (ENaCs). 2017 , 1859, 1040-1048	3
582	Gadolinium-based contrast agents in pediatric magnetic resonance imaging. 2017 , 47, 507-521	34
581	Use of contrast media in computed tomography and magnetic resonance imaging in horses: Techniques, adverse events and opportunities. 2017 , 49, 410-424	23
580	Gadolinium Retention and Toxicity-An Update. 2017 , 24, 138-146	61
579	Contrast Agent-Induced High Signal Intensity in Dentate Nucleus on Unenhanced T1-Weighted Images: Comparison of Gadodiamide and Gadoxetic Acid. 2017 , 52, 389-395	21
578	Functional Magnetic Resonance Imaging of the Kidneys-With and Without Gadolinium-Based Contrast. 2017 , 24, 162-168	3
577	Noncontrast and Contrast-Enhanced Pulmonary Magnetic Resonance Angiography. 2017 , 21-52	1
576	Metal Imaging in the Brain. 2017 , 349-362	0

575	Prognostic value of dynamic MRI positive enhancement integral color mapping in osteosynthesis of undisplaced femoral neck fractures. 2017 , 22, 722-725	3
574	A BMI-adjusted ultra-low-dose CT angiography protocol for the peripheral arteries-Image quality, diagnostic accuracy and radiation exposure. 2017 , 93, 149-156	9
573	Hypersensitivity reactions to gadolinium-based contrast agents. 2017 , 17, 241-246	19
572	Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. 2017 , 52, 396-404	140
571	Gadolinium retention in the body: what we know and what we can do. 2017 , 122, 589-600	55
570	Use of Radiocontrast Agents in CKD and ESRD. 2017 , 30, 290-304	14
569	Use of gadolinium-based magnetic resonance imaging contrast agents and awareness of brain gadolinium deposition among pediatric providers in North America. 2017 , 47, 657-664	29
568	Manganese Complex of Ethylenediaminetetraacetic Acid (EDTA)-Benzothiazole Aniline (BTA) Conjugate as a Potential Liver-Targeting MRI Contrast Agent. 2017 , 60, 2993-3001	33
567	Multiparametric estimation of brain hemodynamics with MR fingerprinting ASL. 2017 , 78, 1812-1823	52
566	Imaging oxygen metabolism with hyperpolarized magnetic resonance: a novel approach for the examination of cardiac and renal function. 2017 , 37,	11
565	Confirming improved detection of gadolinium in bone using in vivo XRF. 2017 , 120, 111-118	12
564	Multifunctional near-infrared dye-magnetic nanoparticles for bioimaging and cancer therapy. 2017 , 390, 168-175	26
563	CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma. 2017 , 40, 177-191	58
562	Contrast Agents for MR Imaging. 2017 , 25, 705-711	12
561	Lung magnetic resonance imaging for pneumonia in children. 2017 , 47, 1420-1430	35
560	Toward inert paramagnetic Ni(II)-based chemical exchange saturation transfer MRI agents. 2017 , 46, 15095-15106	10
559	Metabolomic Analysis of N-acetylcysteine Protection of Injury from Gadolinium-DTPA Contrast Agent in Rats with Chronic Renal Failure. 2017 , 21, 540-549	2
558	Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus. 2017 , 375,	22

557	MRI of the Abdomen. 568-582	
556	Safety of Contrast Material Use in Children. 2017 , 25, 779-785	16
555	Noncontrast Hybrid Arterial Spin-Labeled Imaging of the Intracranial Arteries. 2017 , 41, 854-860	2
554	Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana. 2017 , 23, e108-e113	3
553	Gadobutrol in Renally Impaired Patients: Results of the GRIP Study. 2017 , 52, 55-60	31
552	Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer's disease diagnosis. 2017 , 5, 7216-7237	24
551	MR Venography of the Central Veins of the Thorax. 2017 , 26, 167-174	1
550	Intrathecal Injection of Gadobutrol: A Tale of Caution. 2017 , 31, 139-143	16
549	Gadolinium Retention and Deposition Revisited: How the Chemical Properties of Gadolinium-based Contrast Agents and the Use of Animal Models Inform Us about the Behavior of These Agents in the Human Brain. 2017 , 285, 721-724	14
548	Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies. 2017 , 59, 469-477	6
547	Novel CDTA-based, Bifunctional Chelators for Stable and Inert Mn Complexation: Synthesis and Physicochemical Characterization. 2017 , 56, 7746-7760	24
546	25th Anniversary of European Radiology. 2017 , 27, 1-6	20
545	Editor's Highlight: In Utero Exposure to Gadolinium and Adverse Neonatal Outcomes in Premature Infants. 2017 , 156, 520-526	8
544	Induction of skeletal abnormalities and autophagy in <i>Paracentrotus lividus</i> sea urchin embryos exposed to gadolinium. 2017 , 130, 12-20	20
543	Moderate Renal Failure Accentuates T1 Signal Enhancement in the Deep Cerebellar Nuclei of Gadodiamide-Treated Rats. 2017 , 52, 255-264	36
542	Intrathecal Contrast-Enhanced Magnetic Resonance Imaging-Related Brain Signal Changes: Residual Gadolinium Deposition?. 2017 , 52, 195-197	47
541	Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study). 2017 , 38, 1681-1688	12
540	In vitro chondrocyte toxicity following long-term, high-dose exposure to Gd-DTPA and a novel cartilage-targeted MR contrast agent. 2017 , 46, 23-33	2

539	Diffusion MRI: literature review in salivary gland tumors. 2017 , 23, 572-575	19
538	MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent. 2017 , 27, 2170-2179	32
537	T hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?. 2017 , 90, 20160590	11
536	Low-pass imaging of dynamic acquisitions (LIDA) with a group-oriented registration (GOREG) for proton MR imaging of lung ventilation. 2017 , 78, 1496-1505	28
535	Left atrium: the last bulwark before overt heart failure. 2017 , 22, 123-131	20
534	Gadolinium contrast agents - are they really safe?. 2017 , 18, 1-7	24
533	Synthesis of Multicolor Core/Shell NaLuFâYb/Ln@CaFâUpconversion Nanocrystals. 2017 , 7,	16
532	Gd-Asparagine-Anionic Linear Globular Dendrimer Second-Generation G2 Complexes: Novel Nanobiohybrid Theranostics. 2017 , 2017, 3625729	17
531	A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging. 2017 , 7, 88-122	139
530	Imaging in Rheumatic Diseases. 2017 , 858-907.e8	
529	The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review. 2017 , 12, e0171704	120
528	Proceedings of the International Cancer Imaging Society (ICIS) 17th Annual Teaching Course. 2017 , 17,	1
527	Advocating the Development of Next-Generation High-Relaxivity Gadolinium Chelates for Clinical Magnetic Resonance. 2018 , 53, 381-389	17
526	Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications. 2018 , 9, 857	42
525	Mn ²⁺ complexes of open-chain ligands with a pyridine backbone: less donor atoms lead to higher kinetic inertness. 2018 , 42, 8012-8020	7
524	Do we need gadolinium-based contrast medium for brain magnetic resonance imaging in children?. 2018 , 48, 858-864	4
523	Gd accumulation in tissues of healthy mice upon repeated administrations of Gadodiamide and Gadoteridol. 2018 , 48, 239-245	17
522	Does renal function affect gadolinium deposition in the brain?. 2018 , 104, 33-37	10

521	Renovascular Hypertension. 2018 , 335-346	
520	Gadolinium as an MRI contrast agent. 2018 , 10, 639-661	30
519	Magnetic Resonance Imaging of Articular Cartilage within the Knee. 2018 , 31, 155-165	15
518	Science to Practice: Will Gadolinium Chelates Be Replaced by Iron Chelates in MR Imaging?. 2018 , 286, 409-411	10
517	MRI Contrast Agents. 2018 , 41-51	
516	The use of gadolinium-based contrast agents in Ghana with a focus on residual intracranial gadolinium deposition. 2018 , 24, e51-e55	1
515	Observed Deposition of Gadolinium in Bone Using a New Noninvasive in Vivo Biomedical Device: Results of a Small Pilot Feasibility Study. 2018 , 287, 96-103	44
514	Ferumoxitol-enhanced MR Angiography for Vascular Access Mapping before Transcatheter Aortic Valve Replacement in Patients with Renal Impairment: A Step Toward Patient-specific Care. 2018 , 286, 326-337	20
513	Radiation dose management for pediatric cardiac computed tomography: a report from the Image Gently 'Have-A-Heart' campaign. 2018 , 48, 5-20	21
512	Pediatric Brain: Gadolinium Deposition in Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted Images Is Dependent on the Type of Contrast Agent. 2018 , 53, 246-255	26
511	Editor's Choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). 2018 , 55, 757-818	294
510	Fe Doped Magnetic Nanodiamonds Made by Ion Implantation as Contrast Agent for MRI. 2018 , 8, 7058	16
509	Accurate Monitoring of Renal Injury State through in Vivo Magnetic Resonance Imaging with Ferric Coordination Polymer Nanodots. 2018 , 3, 4918-4923	3
508	Non-invasive detection of the early phase of kidney injury by photoacoustic/computed tomography imaging. 2018 , 29, 265101	3
507	MRI and MRCP for Diagnosis and Staging of Pancreatic Cancer. 2018 , 711-734	2
506	An assessment of exposure to rare earth elements among patients receiving long-term parenteral nutrition. 2018 , 47, 156-163	2
505	Effects of gadolinium-based contrast agents on submandibular gland tissue in rats. 2018 , 275, 1641-1647	0
504	Functional MRI in transplanted kidneys. 2018 , 43, 2615-2624	5

503	10 Years of Nephrogenic Systemic Fibrosis: A Comprehensive Analysis of Nephrogenic Systemic Fibrosis Reports Received by a Pharmaceutical Company from 2006 to 2016. 2018 , 53, 541-550	21
502	A Review of the Current Evidence on Gadolinium Deposition in the Brain. 2018 , 28, 159-169	35
501	Preclinical evaluation of severely defective manganese-based nanocrystal as a liver-specific contrast media for MR imaging: comparison with Gd-EOB-DTPA and MnDPDP. 2018 , 29, 225101	1
500	MRI surveillance of vestibular schwannomas without contrast enhancement: Clinical and economic evaluation. 2018 , 128, 202-209	28
499	Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease. 2018 , 286, 113-119	11
498	Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats. 2018 , 47, 746-752	72
497	Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. 2018 , 123, 125-134	48
496	Gadolinium depositions after the application of the hepatospecific gadolinium-based contrast agent gadoxetate disodium. 2018 , 47, e9-e11	2
495	Gadolinium Chelate Safety in Pregnancy: Barely Detectable Gadolinium Levels in the Juvenile Nonhuman Primate after in Utero Exposure. 2018 , 286, 122-128	31
494	Adverse Reactions to Contrast Media. 2018 , 239-259	0
493	Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments. 2018 , 414, 230-238	44
492	MRI and multiple sclerosis--the evolving role of MRI in the diagnosis and management of MS: the radiologist's perspective. 2018 , 187, 781-787	6
491	Quantitative comparison of delayed ferumoxytol T enhancement with immediate gadoteridol enhancement in high grade gliomas. 2018 , 80, 224-230	7
490	Gadolinium perturbs expression of skeletogenic genes, calcium uptake and larval development in phylogenetically distant sea urchin species. 2018 , 194, 57-66	30
489	A Manganese-based Alternative to Gadolinium: Contrast-enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. 2018 , 286, 865-872	56
488	Myocardial Viability in Ischaemic Heart Disease. 2018 , 347-384	
487	An Introduction to Contrast-Enhanced Ultrasound for Nephrologists. 2018 , 138, 176-185	25
486	Remarkable differences and similarities between the isomeric Mn(II)-cis- and trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetate complexes. 2018 , 472, 254-263	14

- 485 The Diagnosis, Evaluation and Contemporary Management of Acute Limb Ischemia. **2018**, 207-219
- 484 Nephrotoxicity of gadolinium-based contrast in the setting of renal artery intervention: retrospective analysis with 10-year follow-up. **2018**, 24, 378-384 8
- 483 Self-identified gadolinium toxicity: comparison of gadolinium in bone and urine to healthy gadolinium-based contrast agent exposed volunteers. **2018**, 39, 115008 6
- 482 Exposure of Macrophages to Low-Dose Gadolinium-Based Contrast Medium: Impact on Oxidative Stress and Cytokines Production. **2018**, 2018, 3535769 15
- 481 [Non-iodinated contrast media nephrotoxicity]. **2018**, 14, 484-490
- 480 Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan. **2018**, 36, 676-685 9
- 479 Is it safe to use gadolinium-based contrast agents in MRI?. **2017**, 47, 243-246 1
- 478 Synthesis and Evaluation of Manganese(II)-Based Ethylenediaminetetraacetic Acid-Ethoxybenzyl Conjugate as a Highly Stable Hepatobiliary Magnetic Resonance Imaging Contrast Agent. **2018**, 29, 3614-3625 ¹⁰
- 477 Environmental Factors and Their Influence on Intestinal Fibrosis. **2018**, 111-126
- 476 Fe³⁺@polyDOPA-b-polysarcosine, a T1-Weighted MRI Contrast Agent via Controlled NTA Polymerization. **2018**, 7, 693-698 34
- 475 CT imaging of myocardial scar burden with CNA35-conjugated gold nanoparticles. **2018**, 14, 1941-1947 18
- 474 Gadolinium-based contrast agents in children. **2018**, 48, 1188-1196 24
- 473 Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents. **2018**, 84, 2522-2534 61
- 472 Updates in Musculoskeletal Imaging. **2018**, 10, 296-302 3
- 471 Gadobutrol: A Review in Contrast-Enhanced MRI and MRA. **2018**, 38, 773-784 23
- 470 Synthesis of a gadolinium based-macrocyclic MRI contrast agent for effective cancer diagnosis. **2018**, 22, 17 5
- 469 Measurement of gadolinium retention: current status and review from an applied radiation physics perspective. **2018**, 39, 06TR01 4
- 468 MR of the Urogenital Tract in Children. **2018**, 33-91

467	Nierenfunktion bei Kontrastmittelverstärkter Bildgebung. 2018 , 13, 251-261	0
466	Gadolinium Distribution in Cerebrospinal Fluid after Administration of a Gadolinium-based MR Contrast Agent in Humans. 2018 , 288, 703-709	33
465	Safety of Gadolinium Administration in Children. 2018 , 86, 27-32	25
464	The role of magnetic resonance angiography in peripheral artery disease. 2018 , 39, 129-133	4
463	Toxic-induced cerebellar syndrome: from the fetal period to the elderly. 2018 , 155, 333-352	11
462	Effect of blood T1 estimation strategy on arterial spin labeled cerebral blood flow quantification in children and young adults with kidney disease. 2019 , 46, 29-35	6
461	First-Trimester Exposure to Gadolinium-based Contrast Agents: A Utilization Study of 4.6 Million U.S. Pregnancies. 2019 , 293, 193-200	14
460	Gadolinium chloride promotes proliferation of HEK293 human embryonic kidney cells by activating EGFR/PI3K/Akt and MAPK pathways. 2019 , 32, 683-693	1
459	Gadolinium Aspiration Following Inadvertent Endotracheal Tube Cuff Injection in a Pediatric Patient. 2019 , 15, 202-204	
458	Hydroxyl-PEG-Phosphonic Acid-Stabilized Superparamagnetic Manganese Oxide-Doped Iron Oxide Nanoparticles with Synergistic Effects for Dual-Mode MR Imaging. 2019 , 35, 9474-9482	21
457	A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. 2019 , 292, 376-386	45
456	Virtual Elimination of Nephrogenic Systemic Fibrosis: A Medical Success Story with a Small Asterisk. 2019 , 292, 387-389	6
455	Ex vivo quantification of lanthanum and gadolinium in post-mortem human tibiae with estimated barium and iodine concentrations using K x-ray fluorescence. 2019 , 40, 085006	2
454	Nephrogenic systemic fibrosis: the end of the story?. 2019 , 9, 1470-1474	3
453	Computed diffusion-weighted imaging for differentiating synovial proliferation from joint effusion in hand arthritis. 2019 , 39, 2111-2118	1
452	Metal-Based Complexes as Pharmaceuticals for Molecular Imaging of the Liver. 2019 , 12,	4
451	Microextraction of Gadolinium MRI contrast agent using core-shell Fe ₃ O ₄ @SiO ₂ nanoparticles: optimization of adsorption conditions and in-vitro study. 2019 , 12, 100250	2
450	The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists. 2019 , 11, 240-254	66

449	Intravoxel incoherent motion MRI for discrimination of synovial proliferation in the hand arthritis: A prospective proof-of-concept study. 2019 , 50, 1199-1206	3
448	Gadolinium Deposition in the Brain: Current Updates. 2019 , 20, 134-147	71
447	Summary of Imaging in 2020: Visualizing the Future of Healthcare with MR Imaging. 2019 , 21, 193-199	2
446	Contrast Agents in Cardiovascular Magnetic Resonance Imaging. 2019 , 127-143	2
445	Safety and Monitoring for Cardiac Magnetic Resonance Imaging. 2019 , 145-159	
444	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. 2019 , 20, e302-e312	166
443	Compound-specific recording of gadolinium pollution in coastal waters by great scallops. 2019 , 9, 8015	18
442	Noncontrast Magnetic Resonance Angiography for the Diagnosis of Peripheral Vascular Disease. 2019 , 12, e008844	14
441	Contrast media and cutaneous reactions. Part 1. Immediate hypersensitivity reactions to contrast media and gadolinium deposition. 2019 , 44, 839-843	10
440	Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors. 2019 , 375, 32-45	6
439	Non-contrast-enhanced magnetic resonance imaging for visualization and quantification of endovascular aortic prosthesis, their endoleaks and aneurysm sacs at 1.5 T. 2019 , 60, 164-172	7
438	Gadolinium Retention and Clearance in the Diabetic Brain after Administrations of Gadodiamide, Gadopentetate Dimeglumine, and Gadoterate Meglumine in a Rat Model. 2019 , 2019, 3901907	5
437	Pediatric Mediastinal Masses:: Role of MR Imaging as a Problem-Solving Tool. 2019 , 27, 227-242	4
436	Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study. 2019 , 60, 1450-1456	6
435	[Contrast media - Guidelines for practical use]. 2019 , 59, 444-453	2
434	[Kidney function in contrast media-enhanced imaging]. 2019 , 59, 425-434	
433	High resolution, 3-dimensional Ferumoxytol-enhanced cardiovascular magnetic resonance venography in central venous occlusion. 2019 , 21, 17	11
432	In Vitro Safety Evaluation and In Vivo Imaging Studies of Superparamagnetic Iron Oxide Nanoparticles through Biomimetic Modification. 2019 , 2019, 1-9	4

431	Paramagnetic Clusters of Mn(OCCH)(Bpy) in Polyacrylamide Nanobeads as a New Design Approach to a T- T Multimodal Magnetic Resonance Imaging Contrast Agent. 2019 , 11, 18153-18164	4
430	[Gadolinium deposition-"gadolinium deposition disease"]. 2019 , 59, 435-443	2
429	Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents. 2019 , 10, 1420	123
428	Association of Glioma Grading With Inflow-Based Vascular-Space-Occupancy MRI: A Preliminary Study at 3T. 2019 , 50, 1817-1823	9
427	Changes in tissue gadolinium biodistribution measured in an animal model exposed to four chelating agents. 2019 , 37, 458-465	2
426	Metal-based redox-responsive MRI contrast agents. 2019 , 390, 1-31	31
425	Gadolinium-doped bioglass scaffolds promote osteogenic differentiation of hBMSC via the Akt/GSK3 β pathway and facilitate bone repair in vivo. 2019 , 14, 1085-1100	23
424	Standardizing Magnetic Resonance Imaging Protocols, Requisitions, and Reports in Multiple Sclerosis: An Update for Radiologist Based on 2017 Magnetic Resonance Imaging in Multiple Sclerosis and 2018 Consortium of Multiple Sclerosis Centers Consensus Guidelines. 2019 , 43, 1-12	8
423	Gadolinium-based contrast agents: why nephrologists need to be concerned. 2019 , 28, 154-162	15
422	Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents. 2019 , 61, 535-544	17
421	Hydrophilic Quantum Dots Functionalized with Gd(III)-DO3A Monoamide Chelates as Bright and Effective T-weighted Bimodal Nanoprobes. 2019 , 9, 2341	10
420	Spondylodiscitis in end-stage renal disease: a systematic review. 2019 , 1-9	10
419	Nephrogenic Systemic Fibrosis: A Review of History, Pathophysiology, and Current Guidelines. 2019 , 7, 1	9
418	Toxicological assessment of anthropogenic Gadolinium in seawater: Biochemical effects in mussels <i>Mytilus galloprovincialis</i> . 2019 , 664, 626-634	38
417	Non-Contrast-Enhanced Carotid MRA: Clinical Evaluation of a Novel Ungated Radial Quiescent-Interval Slice-Selective MRA at 1.5T. 2019 , 40, 1529-1537	3
416	Assessment of the Relaxation-Enhancing Properties of a Nitroxide-Based Contrast Agent TEEPO-Glc with Magnetic Resonance Imaging. 2019 , 2019, 5629597	0
415	Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. 2019 , 54, 475-484	19
414	Fibrotic Signaling Pathways of Skin Fibroblasts in Nephrogenic Systemic Fibrosis. 2019 , 8, 338-345	

413	Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A. 2019 , 54, 697-703	26
412	The Impact of Different Magnetic Resonance Imaging Equipment and Scanning Parameters on Signal Intensity Ratio Measurements in Phantoms and Healthy Volunteers: Implications for Interpreting Gadolinium Signal Changes Within the Brain. 2019 , 54, 169-176	3
411	The extra miles on preventing nephrogenic systemic fibrosis. 2019 , 9, 1911-1913	1
410	Is it time to relax nephrogenic systemic fibrosis guidelines and safely offer magnetic resonance imaging to more patients?. 2019 , 9, 1918-1921	2
409	The Prognostic Value of Late Gadolinium Enhancement in Nonischemic Heart Disease. 2019 , 27, 545-561	1
408	Elimination of Contrast Agent Gadobutrol with Sustained Low Efficiency Daily Dialysis Compared to Intermittent Hemodialysis. 2019 , 44, 1363-1371	0
407	Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats. 2019 , 54, 61-71	19
406	Assessment of Pharmacokinetic, Pharmacodynamic Profile, and Tolerance of Gadopiclesol, A New High Relaxivity GBCA, in Healthy Subjects and Patients With Brain Lesions (Phase I/IIa Study). 2019 , 54, 396-402	12
405	Elemental analysis in living human subjects using biomedical devices. 2019 , 40, 12TR01	3
404	In vivo Imaging Biodistribution Profile of a New Macrocyclic Gadolinium Chelate as a Highly Stable Multifunctional MRI Contrast Agent. 2019 , 23, 34	
403	Effects of Gadodiamide and Gadoteric Acid on Rat Kidneys: A Comparative Study. 2019 , 49, 382-389	3
402	Nephrogenic systemic fibrosis: in a child with primary hyperoxaluria. 2019 , 44, 70-72	3
401	Noncontrast MR angiography: An update. 2019 , 49, 355-373	39
400	Urinary Gadolinium Levels After Contrast-Enhanced MRI in Individuals with Normal Renal Function: a Pilot Study. 2019 , 15, 121-127	9
399	Utility of arterial spin labelling MRI for discriminating atypical high-grade glioma from primary central nervous system lymphoma. 2019 , 74, 165.e1-165.e9	5
398	MR Imaging Evaluation of the Kidneys in Patients with Reduced Kidney Function: Noncontrast Techniques Versus Contrast-Enhanced Techniques. 2019 , 27, 45-57	2
397	Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents. 2019 , 58, 174-178	9
396	Slow component apparent diffusion coefficient for prostate cancer: Comparison and correlation with pharmacokinetic evaluation from dynamic contrast-enhanced MR imaging. 2019 , 58, 14-17	2

395	MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis. 2019 , 61, 155-162	23
394	Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications. 2019 , 20, 157-167	46
393	LA-ICP-MS/MS improves limits of detection in elemental bioimaging of gadolinium deposition originating from MRI contrast agents in skin and brain tissues. 2019 , 51, 212-218	27
392	Epidemiology and Biostatistics. 2019 ,	8
391	Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. 2019 , 119, 957-1057	549
390	Cardiac Magnetic Resonance Imaging. 2019 , 511-521	
389	Chemical Insights into the Issues of Gd Retention in the Brain and Other Tissues Upon the Administration of Gd-Containing MRI Contrast Agents. 2019 , 2019, 137-151	21
388	Evaluating the Patient with Reported Gadolinium-Associated Illness. 2019 , 15, 36-44	8
387	Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. 2019 , 29, 1922-1930	18
386	Non-contrast-enhanced magnetic resonance angiography for detecting crossing renal vessels in infants and young children: comparison with contrast-enhanced angiography and surgical findings. 2019 , 49, 105-113	
385	Monitoring of acoustic cavitation in microbubble-presented focused ultrasound exposure using gradient-echo MRI. 2020 , 51, 311-318	1
384	Monitoring diffuse injury during disease progression in experimental autoimmune encephalomyelitis with on resonance variable delay multiple pulse (onVDMP) CEST MRI. 2020 , 204, 116245	5
383	Trace Elements in Chronic Kidney Disease. 2020 , 703-717	1
382	Recent advances in the development of nanoparticles for multimodality imaging and therapy of cancer. 2020 , 40, 909-930	18
381	Deep learning how to fit an intravoxel incoherent motion model to diffusion-weighted MRI. 2020 , 83, 312-321	30
380	Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study. 2020 , 51, 607-614	7
379	Manganese-Based Functional Nanoplatfoms: Nanosynthetic Construction, Physiochemical Property, and Theranostic Applicability. 2020 , 30, 1907066	49
378	Effect of intravenously injected gadolinium-based contrast agents on functional lung parameters derived by PREFUL MRI. 2020 , 83, 1045-1054	2

377	Sclerodermalike syndromes: Great imitators. 2020 , 38, 235-249	9
376	Updated guidelines for intravenous contrast use for CT and MRI. 2020 , 27, 115-126	9
375	Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI. 2020 , 294, 398-404	32
374	Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients. 2020 , 51, 861-868	6
373	Highly accelerated vessel-selective arterial spin labeling angiography using sparsity and smoothness constraints. 2020 , 83, 892-905	3
372	Noncontrast T2-Weighted Magnetic Resonance Imaging Sequences for Long-Term Monitoring of Asymptomatic Convexity Meningiomas. 2020 , 135, e100-e105	4
371	Gadolinium Retention and Breast MRI Screening: More Harm Than Good?. 2020 , 214, 324-327	10
370	Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease-Is Zero Good Enough?. 2020 , 180, 230-232	3
369	Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents. 2020 , 30, 1790-1803	11
368	Decreased native renal T up to one week after gadobutrol administration in healthy volunteers. 2020 , 52, 622-631	1
367	Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI. 2020 , 41, 170-182	13
366	Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer. 2020 , 40, 153-162	36
365	Yttrium-86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents. 2020 , 59, 1474-1478	14
364	New Strategies in the Design of Paramagnetic CAs. 2020 , 2020, 4327479	4
363	Adverse drug reactions: five historical scandals. 2020 , 324, 1255-1258	0
362	Magnetic Resonance Safety: Pregnancy and Lactation. 2020 , 28, 509-516	3
361	Assessment of marine macroalgae potential for gadolinium removal from contaminated aquatic systems. 2020 , 749, 141488	11
360	Risk of Nephrogenic Systemic Fibrosis from Gadoteric Acid in Patients with Severe Kidney Disease. 2020 , 297, 563-564	1

359	Improved Stability and Photothermal Performance of Polydopamine-Modified Fe O Nanocomposites for Highly Efficient Magnetic Resonance Imaging-Guided Photothermal Therapy. 2020 , 16, e2003969	33
358	An Efficient Route for Synthesis of Macrocyclic Gadolinium Complexes and Their Role in Medical Applications. 2020 ,	
357	Mono-dispersed nano-hydroxyapatite based MRI probe with tetrahedral DNA nanostructures modification for in vitro tumor cell imaging. 2020 , 1138, 141-149	4
356	Systemic sclerosis: Update for oral health care providers. 2020 , 40, 418-430	2
355	Manganese Complex of a Rigidified 15-Membered Macrocycle: A Comprehensive Study. 2020 , 59, 11366-113763	
354	Current and Future MR Contrast Agents: Seeking a Better Chemical Stability and Relaxivity for Optimal Safety and Efficacy. 2020 , 55, 578-588	12
353	Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis. 2020 , 50, 1226-1237	3
352	Effect of contrast dose on diagnostic performance in DCE-MR breast imaging. 2020 , 21, 188-194	
351	Gadolinium Complexes Attached to Poly Ethoxy Ethyl Glycinamide (PEE-G) Dendrons: Magnetic Resonance Imaging Contrast Agents with Increased Relaxivity. 2020 , 85, 1881-1892	3
350	Mn Complexes Containing Sulfonamide Groups with pH-Responsive Relaxivity. 2020 , 59, 14306-14317	5
349	Onko-Nephrologie. 2020 ,	
348	Applications for Transition-Metal Chemistry in Contrast-Enhanced Magnetic Resonance Imaging. 2020 , 59, 6648-6678	35
347	Gadolinium Deposition Safety: Seeking the Patient's Perspective. 2020 , 41, 944-946	6
346	Mn(II)-Based MRI Contrast Agent Candidate for Vascular Imaging. 2020 , 63, 6057-6065	19
345	Macrocyclic Pycen-Based Gd Complex with High Relaxivity and pH Response. 2020 , 59, 7306-7317	3
344	Anthropogenic gadolinium in freshwater and drinking water systems. 2020 , 182, 115966	14
343	Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration. 2020 , 41, 393-399	4
342	Identification and characterization of Gd-binding proteins in NIH-3T3 cells. 2020 , 219, 121281	5

341	Metal Nanoparticles in Infection and Immunity. 2020 , 49, 794-807	8
340	Gadolinium complexes of macrocyclic diethylenetriamine-N-oxide pentaacetic acid-bisamide as highly stable MRI contrast agents with high relaxivity. 2020 , 49, 8927-8932	8
339	Radicontrast Toxicity. 2020 , 27, 50-55	3
338	WITHDRAWN: Risks and Benefits of Gadolinium-Based Contrast Enhanced MRI. 2020 , 41, 260-274	1
337	Absence of T1 Hyperintensity in the Brain of High-risk Patients After Multiple Administrations of High-dose Gadobutrol for Cardiac Magnetic Resonance. 2021 , 31, 347-355	1
336	Synthesis and in vivo behaviour of an exendin-4-based MRI probe capable of cell-dependent contrast enhancement in the pancreas. 2020 , 49, 4732-4740	4
335	MnO Nanoparticles Embedded in Functional Polymers as T1 Contrast Agents for Magnetic Resonance Imaging. 2020 , 3, 3787-3797	12
334	Is Small Fiber Neuropathy Induced by Gadolinium-Based Contrast Agents?. 2020 , 55, 473-480	7
333	Corbicula fluminea: A sentinel species for urban Rare Earth Element origin. 2020 , 732, 138552	12
332	Strategies to Reduce the Use of Gadolinium-Based Contrast Agents for Abdominal MRI in Children. 2020 , 214, 1054-1064	7
331	Enhancing P NMR relaxation rates with a kinetically inert gadolinium complex. 2020 , 49, 2989-2993	3
330	SLIC-supervoxels-based response evaluation of osteosarcoma treated with neoadjuvant chemotherapy using multi-parametric MR imaging. 2020 , 30, 3125-3136	2
329	Yttrium-86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents. 2020 , 132, 1490-1494	0
328	Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents. 2020 , 55, 138-143	12
327	Accuracy of non-contrast quiescent-interval single-shot and quiescent-interval single-shot arterial spin-labelled magnetic resonance angiography in assessment of peripheral arterial disease in a diabetic population. 2020 , 64, 35-43	4
326	Dose Finding Study of Gadopiclesol, a New Macrocyclic Contrast Agent, in MRI of Central Nervous System. 2020 , 55, 129-137	4
325	Stable and Inert Mn(II)-Based and pH-Responsive Contrast Agents. 2020 , 142, 1662-1666	41
324	Gadolinium retention - 5 years later. 2020 , 50, 166-167	1

323	Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation. 2020 , 50, 388-396	36
322	Atlas of Clinical Cases on Brain Tumor Imaging. 2020 ,	1
321	Unexpected Trends in the Stability and Dissociation Kinetics of Lanthanide(III) Complexes with Cyclen-Based Ligands across the Lanthanide Series. 2020 , 59, 8184-8195	11
320	Rapid Detection of Gadolinium-Based Contrast Agents in Urine with a Chelated Europium Luminescent Probe. 2020 , 5, 1281-1286	13
319	Brain MRIs make up the bulk of the gadolinium footprint in medical imaging. 2020 , 47, 259-265	4
318	Investigation of potential adverse central nervous system effects after long term oral administration of gadolinium in mice. 2020 , 15, e0231495	8
317	Unprecedented Kinetic Inertness for a Mn ²⁺ -Bispidine Chelate: A Novel Structural Entry for Mn ²⁺ -Based Imaging Agents. 2020 , 132, 12056-12061	4
316	Unprecedented Kinetic Inertness for a Mn ²⁺ -Bispidine Chelate: A Novel Structural Entry for Mn ²⁺ -Based Imaging Agents. 2020 , 59, 11958-11963	24
315	Presence of other rare earth metals in gadolinium-based contrast agents. 2020 , 216, 120940	4
314	Strategic reconstruction of macrophage-derived extracellular vesicles as a magnetic resonance imaging contrast agent. 2020 , 8, 2887-2904	15
313	Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change. 2020 , 76, 436-439	2
312	Randomized study of the effect of gadopiclesol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects. 2020 , 86, 2174-2181	1
311	Evaluation of toxicity of gadolinium-based contrast agents on neuronal cells. 2021 , 62, 206-214	3
310	Quantitative Evaluation of Equine Articular Cartilage Using Cationic Contrast-Enhanced Computed Tomography. 2021 , 12, 211-221	4
309	Speciation analysis of Gadolinium-based contrast agents using aqueous eluent-hydrophilic interaction liquid chromatography hyphenated with inductively coupled plasma-mass spectrometry. 2021 , 222, 121531	4
308	Lifecycle of Gadolinium-Based Contrast Agents. 2021 , 53, 1295-1299	0
307	Recent progress on nanoparticles for targeted aneurysm treatment and imaging. 2021 , 265, 120406	6
306	Cardiac Imaging for Coronary Heart Disease Risk Stratification in Chronic Kidney Disease. 2021 , 14, 669-682	14

305	Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma. 2021 , 496, 169-178	11
304	Maltodextrin-Conjugated Gd-Based MRI Contrast Agents for Specific Diagnosis of Bacterial Infections.. 2021 , 4, 3762-3772	3
303	A step towards gadolinium-free bioresponsive MRI contrast agent. 2021 , 211, 113086	2
302	Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles. 2021 , 155, 19-73	1
301	Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. 2021 , 298, 28-35	27
300	Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. 2021 , 3, 142-150	8
299	Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). 2021 , 31, 100693	1
298	Microdistribution of Magnetic Resonance Imaging Contrast Agents in Atherosclerotic Plaques Determined by LA-ICP-MS and SR-XRF Imaging. 2021 , 23, 382-393	6
297	Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. 2021 , 77, 517-528	10
296	Toxicity associated with gadolinium-based contrast-enhanced examinations. 2021 , 8, 198-220	1
295	Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems. 2021 , 13,	5
294	Nonclinical Product Developmental Strategies, Safety Considerations and Toxicity Profiles of Medical Imaging and Radiopharmaceuticals Products. 2021 , 717-735	
293	Stability, relaxometric and computational studies on Mn complexes with ligands containing a cyclobutane scaffold. 2021 , 50, 1076-1085	2
292	Iron(iii) chelated paramagnetic polymeric nanoparticle formulation as a next-generation -weighted MRI contrast agent.. 2021 , 11, 32216-32226	3
291	Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents. 2021 , 50, 1419-1425	1
290	Alternatives to Gadolinium-Based Contrast Agents. 2021 , 56, 35-41	3
289	NSF: Real or Hype?. 2021 , 59-66	
288	Gadolinium distribution in kidney tissue determined and quantified by micro synchrotron X-ray fluorescence. 2021 , 34, 341-350	0

287	Contrast Agent Use and Safety in Pediatric Patients. 2021 , 249-257	
286	Neuroimaging of central diabetes insipidus. 2021 , 181, 207-237	0
285	Preoperative evaluation of iliac blood vessels for first kidney transplant recipients: Combination of conventional and contrast-enhanced ultrasonography. 2021 , 78, 139-149	
284	Ischemic Stroke Increased Gadolinium Deposition in the Brain and Aggravated Astrocyte Injury After Gadolinium-Based Contrast Agent Administration: Linear Versus Macrocyclic Agents. 2021 , 53, 1282-1292	0
283	Gadolinium Concentrations in Biological Matrices From Patients Exposed to Gadolinium-Based Contrast Agents. 2021 , 56, 458-464	2
282	Signal Intensity Evaluation in the Dentate Nucleus and Subcortical Gray Matter : Effect of Several Administrations of Gadoterate Meglumine in Multiple Sclerosis. 2021 , 1	0
281	Iron(III)-tCDTA derivatives as MRI contrast agents: Increased T relaxivities at higher magnetic field strength and pH sensing. 2021 , 85, 3370-3382	5
280	Deep learning-based methods may minimize GBCA dosage in brain MRI. 2021 , 31, 6419-6428	5
279	Expanding the Ligand Classes Used for Mn(II) Complexation: Oxa-aza Macrocycles Make the Difference. 2021 , 26,	2
278	PVP-coated Gd-grafted nanodiamonds as a novel and potentially safer contrast agent for in vivo MRI. 2021 , 86, 935-942	13
277	Repeated gadoteric acid and gadobutrol exposure causes deterioration of behavior and memory functions in rats: MRI, histopathological and biochemical evidence. 2021 , 1754, 147256	2
276	Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging. 2021 , 46, 3995-4001	1
275	Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review. 2021 , 18,	5
274	A Single-Pot Template Reaction Towards a Manganese-Based T1 Contrast Agent. 2021 , 133, 10831-10839	0
273	A Single-Pot Template Reaction Towards a Manganese-Based T Contrast Agent. 2021 , 60, 10736-10744	15
272	Metal-based environment-sensitive MRI contrast agents. 2021 , 61, 154-169	5
271	Genome-wide toxicogenomic study of the lanthanides sheds light on the selective toxicity mechanisms associated with critical materials. 2021 , 118,	8
270	Ultra-small size gelatin nanogel as a blood brain barrier impermeable contrast agent for magnetic resonance imaging. 2021 , 125, 290-299	12

269	A generic deep learning model for reduced gadolinium dose in contrast-enhanced brain MRI. 2021 , 86, 1687-1700	2
268	Comprehensive Literature Review of Hyperpolarized Carbon-13 MRI: The Road to Clinical Application. 2021 , 11,	4
267	Safety issues related to intravenous contrast agent use in magnetic resonance imaging. 2021 , 51, 736-747	5
266	Nephrogenic systemic fibrosis: A frivolous entity. 2021 , 10, 29-36	4
265	Magnetic Resonance Detection of Gas Microbubbles via HyperCEST: A Path Toward Dual Modality Contrast Agent. 2021 , 22, 1219-1228	1
264	Ferumoxytol-enhanced vascular suppression in magnetic resonance neurography. 2021 , 50, 2255-2266	1
263	Dendrimers based cancer nanotheranostics: An overview. 2021 , 600, 120485	6
262	Editorial for "Gadolinium Clearance in the First 5 Weeks After Repeated Intravenous Administration of Gadoteridol, Gadoterate Meglumine and Gadobutrol to rats". 2021 , 54, 1645-1646	1
261	Highly Efficient Activatable MRI Probe to Sense Myeloperoxidase Activity. 2021 , 64, 5874-5885	3
260	Comparison of 1.5 T and 3 T non-contrast-enhanced MR angiography for visualization of uterine and ovarian arteries before uterine artery embolization. 2022 , 32, 470-476	1
259	7T dynamic contrast-enhanced MRI for the detection of subtle blood-brain barrier leakage. 2021 , 31, 902-911	1
258	Harnessing methylotrophs as a bacterial platform to reduce adverse effects of the use of the heavy lanthanide gadolinium in magnetic resonance imaging.	1
257	Development of radiopharmaceuticals for PET renography. 2021 , 133, 1	
256	Can Deep Learning Replace Gadolinium in Neuro-Oncology?: A Reader Study. 2021 ,	0
255	Musculoskeletal magnetic resonance imaging in the DE50-MD dog model of Duchenne muscular dystrophy. 2021 , 31, 736-751	2
254	Complexes of Bifunctional DO3A-N-(β -amino)propionate Ligands with Mg(II), Ca(II), Cu(II), Zn(II), and Lanthanide(III) Ions: Thermodynamic Stability, Formation and Dissociation Kinetics, and Solution Dynamic NMR Studies. 2021 , 26,	1
253	Synthesis of Biomimetic Melanin-Like Multifunctional Nanoparticles for pH Responsive Magnetic Resonance Imaging and Photothermal Therapy. 2021 , 11,	1
252	Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: In Training. 2021 , 300, 279-284	1

251	Gadolinium-free Magnetic Resonance Imaging of the Liver using an Oatp1-targeted Manganese(III) Porphyrin.	0
250	Contrast-Free Detection of Focused Ultrasound-Induced Blood-Brain Barrier Opening Using Diffusion Tensor Imaging. 2021 , 68, 2499-2508	3
249	Stability of MRI contrast agents in high-energy radiation of a 1.5T MR-Linac. 2021 , 161, 55-64	2
248	Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference. 2021 ,	3
247	What do we know about the ecotoxicological implications of the rare earth element gadolinium in aquatic ecosystems?. 2021 , 781, 146273	14
246	Effects of Gadolinium Deposition in the Brain on Motor or Behavioral Function: A Mouse Model. 2021 , 301, 409-416	1
245	Gadolinium Retention: What Do We Know?. 2021 , 301, 643-644	0
244	Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75). 2021 , 217, 1195-1205	0
243	Potential toxicity evaluation and comparison within multiple mice organs after repeat injections of linear versus macrocyclic gadolinium-based contrast agents: A comprehensive and time course study. 2021 , 350, 152-161	1
242	Ratiometric magnetic resonance imaging: Contrast agent design towards better specificity and quantification. 2021 , 447, 214150	3
241	Magnetic Resonance Imaging of the Knee. 2022 , 29-49	
240	Neuromuscular Manifestations of Acquired Metabolic, Endocrine, and Nutritional Disorders. 2022 , 528-553	
239	Cyclodextrins: promising scaffolds for MRI contrast agents.. 2021 , 11, 29762-29785	0
238	Role of Radiological Assessment and Intervention in Pediatric Dialysis. 2021 , 709-724	
237	Metal Complexes as T1 MRI Contrast Agents. 2021 , 741-770	
236	Potential Anthropogenic Pollution of High-technology Metals with a Focus on Rare Earth Elements in Environmental Water. 2021 , 37, 131-143	2
235	Magnets, Magnetism, and Magnetic Resonance Imaging: History, Basics, Clinical Aspects, and Future Directions. 2021 , 135-161	1
234	Nephrogenic Systemic Fibrosis. 2015 , 119-136	1

233	Gadolinium and Nephrogenic Systemic Fibrosis. 2008 , 515-517	5
232	Pregnancy and Lactation. 2009 , 95-101	3
231	Delayed Reactions: Nephrogenic Systemic Fibrosis. 2009 , 187-196	1
230	Pharmacovigilance: When to Report Adverse Reactions. 2009 , 21-23	1
229	Intravascular Contrast Media for Radiology, CT and MRI. 2008 , 31-53	3
228	Systemic Sclerosis and the Scleroderma-Spectrum Disorders. 2009 , 1311-1351	8
227	Dermatologic Conditions in Kidney Disease. 2012 , 2156-2168	1
226	ACR Appropriateness Criteria□ Indeterminate Renal Mass. 2020 , 17, S415-S428	9
225	Lâimagerie mēdicale diagnostique est-elle iatrogēne ?. 2014 , 198, 725-743	1
224	Gadolinium-associated nephrogenic systemic fibrosis. 2008 , 5, 325-326	1
223	Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model. 2019 , 9, 709	3
222	Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats. 2020 , 10, 22385	5
221	A reference set of curated biomedical data and metadata from clinical case reports. 2018 , 5, 180258	14
220	Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). 2007 , 42, 139-45	167
219	Immunohistochemical aspects of the fibrogenic pathway in nephrogenic systemic fibrosis. 2010 , 18, 448-52	6
218	Noncontrast Magnetic Resonance Angiography in the Era of Nephrogenic Systemic Fibrosis and Gadolinium Deposition. 2021 , 45, 37-51	3
217	Positron Emission Tomography-Magnetic Resonance Imaging Pharmacokinetics, In Vivo Biodistribution, and Whole-Body Elimination of Mn-PyC3A. 2021 , 56, 261-270	4
216	Peripheral arterial disease: current perspectives and new trends in management. 2009 , 102, 1141-9	26

215	A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR. 2017 , 2017,	9
214	Dynamic MR angiography of upper extremity vascular disease: pictorial review. 2008 , 28, e28	32
213	Nephrogenic systemic fibrosis in Denmark--a nationwide investigation. 2013 , 8, e82037	13
212	Non-enhanced T1-weighted liver vessel imaging at 7 Tesla. 2014 , 9, e97465	7
211	Quantitative estimation of renal function with dynamic contrast-enhanced MRI using a modified two-compartment model. 2014 , 9, e105087	5
210	3D contrast enhancement-MR angiography for imaging of unruptured cerebral aneurysms: a hospital-based prevalence study. 2014 , 9, e114157	9
209	Diagnostic Magnetic Resonance Imaging of Atherosclerosis in Apolipoprotein E Knockout Mouse Model Using Macrophage-Targeted Gadolinium-Containing Synthetic Lipopeptide Nanoparticles. 2015 , 10, e0143453	17
208	New generation of oxide-based nanoparticles for the applications in early cancer detection and diagnostics. 2020 , 9, 274-302	8
207	Development and use of iron oxide nanoparticles (Part 2): The application of iron oxide contrast agents in MRI. 2010 , 6,	15
206	Contrast medium-induced nephropathy. Aspects on incidence, consequences, risk factors and prevention. 2007 , 2, 118-124	2
205	[Nephrogenic systemic fibrosis and use of MR contrast media]. 2009 , 129, 180-2	1
204	Nephrogenic systemic fibrosis: a brief review. 2011 , 56, 54-8	5
203	Nephrogenic systemic fibrosis: current concepts. 2011 , 56, 59-64	9
202	Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. 2011 , 56, 65-73	20
201	Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function. 2017 , 27, 141-147	40
200	Nephrogenic fibrosing dermatopathy, cardiac calcification and pulmonary hypertension in an adolescent on chronic hemodialysis. 2008 , 18, 70-3	6
199	Comparison of Magnetic Resonance Urography (MRU) with Intravenous Pyelography (IVP) in Evaluation of Patients with Hydronephrosis on Ultrasonography Due to Pelvi-Ureteric Junction Obstruction. 2016 , 07, 353-360	1
198	Renal Transplantation Is Associated with Improved Clinical Outcomes in Nephrogenic Systemic Fibrosis. 2013 , 2013, 1-10	1

197	Nephrogenic systemic fibrosis: a pathologic study of autopsy cases. 2009 , 133, 1943-8	32
196	The role of gadolinium in triggering nephrogenic systemic fibrosis/nephrogenic fibrosing dermatopathy. 2007 , 131, 1515-6	5
195	Revisiting the factors influencing the magnetic resonance contrast of Gd ₂ O ₃ nanoparticles.	0
194	MRI relaxation agents based on transition metals. 2021 , 78, 109-142	0
193	Use of Iodinated and Gadolinium-Containing Contrast Media in CKD. 2022 , 395-409	
192	The history of magnetic resonance imaging and its reflections in. 2021 , 62, 1481-1498	2
191	Gadolinium – specific trigger for the development of nephrogenic fibrosing dermatopathy and nephrogenic systemic fibrosis?. 2007 , 2007, 285-286	
190	A case of nephrogenic systemic fibrosis (NSF) possibly related to gadolinium-based contrast media (Gadodiamide) administration. 2007 , 40, 805-810	1
189	Contrast medium-induced nephropathy. Aspects on incidence, consequences, risk factors and prevention. 2007 , 2, 118-24	2
188	[Nephrogenic systemic fibrosis]. 2007 , 148, 1801-4	
187	Abdominal Computed Tomographic Angiography. 2008 , 141-152	
186	Neurological Complications of Imaging Procedures. 2008 , 999-1013	
185	Imaging agents. 2008 , 699-724	
184	Gadolinium-Based Contrast Media Used in Magnetic Resonance Imaging. 2008 , 81-83	
183	Contrast Agents in Neuroradiological MRI: Current Status. 2008 , 150-157	
182	Nephrogenic Systemic Fibrosis and Other Scleroderma Mimickers. 2009 , 97-106	
181	Lymphangiogenesis and Imaging of the Lymphatics in Cancer. 2009 , 159-184	
180	Magnetic Resonance Imaging. 2009 , 56-79	

179 Kidney. **2009**, 1863-1952

0

178 Contrast Media for MRI of the Gastrointestinal Tract. **2010**, 33-49

177 Magnetic Resonance Imaging. **2010**, 345-370

176 Renovascular Hypertension. **2010**, 293-304

175 Arteriography. **2010**, 285-304

174 Technical Aspects of Pediatric Cardiac MR. 17-32

2

173 Cardiac Magnetic Resonance Imaging. **2011**, 567-579

172 Principles of Radiological Imaging of the Urinary Tract. **2010**, 83-102

171 Magnetresonanztomographie (MRT). **2011**, 339-356

170 Neoplasms of the Kidney and Bladder. **2011**, 1049-1068

169 A 65-Year-Old Woman with Hardened Skin, Joint Contractures, and Yellow Scleral Plaques. **2011**, 85-94

168 Pathogenesis of systemic sclerosis. **2011**, 1387-1402.e5

167 Nephrogenic systemic fibrosis: time for the requiem?. **2011**, 56, 52-3

166 MRI of the Liver. **2011**, 529-536

165 Vraies et fausses contre-indications de lâIRM cardiaque. **2011**, 79-85

164 Cutaneous Manifestations of Renal Disease. **2012**, 31-40

163 Use of Contrast Agents in Children with Chronic Kidney Disease. **2012**, 629-642

162 CE-MRA in the Age of Nephrogenic Systemic Fibrosis. **2012**, 387-394

161 Renal Vascular Diseases. **2012**, 283-295

160 Low-Dose Contrast-Enhanced MR Angiography. **2012**, 107-112

159 Neuro-ophthalmology Approach to Oculoplastic Disorders. **2012**, 139-164

158 Therapeutic Agents for Spine Injection. **2012**, 16-27

157 Study of Role of Magnetic Resonance Urography (MRU) and Comparison with Conventional Radiology in the Diagnosis of Complex Renal Anomalies: A Tertiary Care Centre Experience. **2012**, 02, 113-118

156 Medications. **2012**, 78-84

155 Urinary Tract Imaging. **2012**, 99-139.e3

2

154 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80

153 Diagnostic Kidney Imaging. **2012**, 930-1005

152 Renal Artery Stenosis. **2012**, 538-547

151 Contrast Agents in Carotid Angiography with Magnetic Resonance. **2014**, 65-71

150 Nephrogenic Systemic Fibrosis. **2014**, 247-254

149 Aortoiliac Assessment: MRA. **2014**, 273-288

148 MR Perfusion Imaging: ASL, T2*-Weighted DSC, and T1-Weighted DCE Methods. **2014**, 3-25

147 Workflow and Practical Logistics. **2014**, 43-52

146 Principles of Magnetic Resonance Imaging (MRI). **2014**, 41-65

145 Urologic Issues in the Renal Transplant Patient. **2014**, 341-353

144 Scanning Electron Microscopy : the Past, the Present and the Future. **2014**, 76, 435-441

- 143 Contrast Media-Induced Nephropathy and Nephrogenic Systemic Fibrosis. **2014**, 825-837
- 142 MRI for Interventions and Surgery. **2014**, 1-14
- 141 Diseases of Renal Macrocirculation: Atherosclerosis and Renal Artery Stenosis. **2014**, 1-26
- 140 Preoperative and Postoperative Radiological Assessment. **2014**, 353-366
- 139 Management of Peripheral Arterial Disease. 267-305
- 138 Renal Insufficiency and Necrosis. **2015**, 155-158
- 137 [Contrast agents in MRI-diagnosis of multiple sclerosis]. **2015**, 115, 58-65
- 136 Miscellaneous arthropathies. **2015**, 1420-1431
- 135 Magnetresonanztomographie (MRT) â€”Komponenten und Methoden. **2015**, 1-22
- 134 Contrast Media. **2015**, 271-281
- 133 Magnetic Resonance Imaging for Interventions and Surgery. **2015**, 3397-3407
- 132 Diseases of Renal Macrocirculation: Atherosclerosis and Renal Artery Stenosis. **2015**, 3715-3737
- 131 Introduction to Renal Physiology and Contrast. **2016**, 114-115
- 130 Gadolinium. **2016**, 491-504
- 129 Magnetic Resonance Imaging in Acute and Chronic Limb Ischemia. **2017**, 183-198
- 128 Magnetresonanztomographie (MRT). **2017**, 323-344
- 127 Rare Earth Element Toxicity to Marine and Freshwater Algae. **2016**, 155-166
- 126 Gadolinium-Induced Fibrosis. **2017**, 209-237

- 125 MRI and MRCP for Diagnosis and Staging of Pancreatic Cancer 2nd Ed. **2017**, 1-24
- 124 Unenhanced renal magnetic resonance angiography in patients with chronic kidney disease & suspected renovascular hypertension: Can it affect patient management?. **2017**, 146, S22-S29 4
- 123 Magnetic Materials for Nuclear Magnetic Resonance and Magnetic Resonance Imaging. **2017**, 131-188
- 122 Patient Perception of Lower Limb Non-Contrast Magnetic Resonance Angiography and Digital Subtraction Angiography in Diabetic Patients with Peripheral Arterial Disease. **2017**, 1, 240 2
- 121 Nierenerkrankungen und Hypertonie in der Neurologie. **2018**, 1-20
- 120 Introduction to the Kidney, Renal Physiology, and Contrast. **2018**, 68-71
- 119 Evaluation of Collateral Circulation in Is-chemic Stroke. **2018**, 08, 1000-1007
- 118 Causal Relationships in Health and Disease. **2019**, 3-10
- 117 Cardiovascular Magnetic Resonance Angiography. **2019**, 518-528.e5
- 116 Cardiovascular Magnetic Resonance Contrast Agents. **2019**, 27-39.e4
- 115 MRI with Contrast Enhancement in a Patient with Chronic Kidney Disease: to Contrast Have Not Be Denied. Where Should We Put the Comma?. **2019**, 100, 58-66
- 114 Highly Accelerated Vessel-Selective Arterial Spin Labelling Angiography using Sparsity and Smoothness Constraints.
- 113 Benign and Malignant Diseases of the Prostate. **2020**, 1-32
- 112 Evaluation of Cerebral Blood Flow Using Arterial Spin Labeling in Patients with Chronic Kidney Disease. **2020**, 81, 912
- 111 Brain Tumour Imaging: Developing Techniques and Future Perspectives. **2020**, 81-92
- 110 Use of Gadolinium-Based Contrast Agents in Patients with Severe Renal Impairment. Absence of Risk Versus Caution: A Nephrologist's Perspective.. **2020**, 1, 433-435
- 109 Gadolinium In Medicine-An Evaluation and Update. 1-7
- 108 The Pattern of Use, Effectiveness, and Safety of Gadoteric Acid (Clariscan) in Patients Undergoing Contrast-Enhanced Magnetic Resonance Imaging: A Prospective, Multicenter, Observational Study. **2021**, 2021, 4764348 1

107	Neutrophil elastase in the development of nephrogenic systemic fibrosis (NSF)-like skin lesion in renal failure mouse model. 2021 , 16, e0259211	
106	Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention. 2021 , 193, 1010-1018	0
105	Comparison of phase-resolved functional lung (PREFUL) MRI derived perfusion and ventilation parameters at 1.5T and 3T in healthy volunteers. 2020 , 15, e0244638	1
104	L-EGCG-Mn nanoparticles as a pH-sensitive MRI contrast agent. 2021 , 28, 134-143	2
103	Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: PRO.. 2021 , 2, 10-12	1
102	Ferumoxitol-enhanced MR Venography of the Central Veins of the Thorax for the Evaluation of Stenosis and Occlusion in Patients with Renal Impairment. 2020 , 2, e200339	
101	Gd/Y Hydroxide Nanosheets as Highly Efficient T/T MRI Contrast Agents. 2020 , 11,	1
100	Trace elements, toxic metals, and metalloids in kidney disease. 2022 , 467-488	
99	Benign and Malignant Diseases of the Prostate. 2020 , 651-682	
98	Maligne Erkrankungen bei chronischer Niereninsuffizienz. 2020 , 271-297	
97	Nierenerkrankungen und Hypertonie in der Neurologie. 2020 , 1763-1781	
96	Pulmonary Embolism. 2020 , 349-363	
95	Gadolinium-Based Contrast Agents for Breast MRI and Uncertainties About Brain Gadolinium Retention. 2020 , 63-82	0
94	Glycosaminoglycans as Novel Targets for in vivo Contrast-Enhanced Magnetic Resonance Imaging of Atherosclerosis. 2020 , 5, 080-088	
93	FIBROSIS: POLYETIOLOGIC COMPLICATION WITH COMMON DENOMINATOR. 2021 , 90-99	1
92	-acetylcysteine-PLGA nano-conjugate: effects on cellular toxicity and uptake of gadopentate dimeglumine. 2020 , 14, 470-478	2
91	Contrast-Induced Nephropathy. 2009 , 275-280	
90	Nephrogenic systemic fibrosis: a concise review for cardiologists. 2010 , 37, 508-15	14

89	Use of GBCA in MRIs for High-Risk Patients. 2019 , 36, 152-153	
88	[T-weighted magnetic resonance imaging contrast agents and their theranostic nanoprobes]. 2020 , 40, 427-444	1
87	Failure mode and effects analysis (FMEA) to enhance the safety and efficiency of Gamma Knife radiosurgery. 2020 , 7, 115-125	1
86	Myocardial blood flow is the dominant factor influencing cardiac magnetic resonance adenosine stress T2. 2021 , e4643	1
85	Weighted Linear Regression Improves Accuracy of Quantitative Elemental Bioimaging by Means of LA-ICP-MS. 2021 , 93, 15720-15727	2
84	Iron Oxide-Coated Dextran Nanoparticles with Efficient Renal Clearance for Musculoskeletal Magnetic Resonance Imaging.	
83	A New Oxygen Containing Pyclyen-Type Ligand as a Manganese(II) Binder for MRI and Mn PET Applications: Equilibrium, Kinetic, Relaxometric, Structural and Radiochemical Studies.. 2022 , 27,	0
82	13 Cutaneous mucinoses. 2010 , 317-327	
81	Dendrimer-Based Nanomedicine (Paramagnetic Nanoparticle, Nanocombretastatin, Nanocurcumin) for Glioblastoma Multiforme Imaging and Therapy.. 2021 , 6, 609-614	
80	Tannin-Mn coordination polymer coated carbon quantum dots nanocomposite for fluorescence and magnetic resonance bimodal imaging.. 2022 , 33, 16	1
79	Delineating toxicity mechanisms associated with MRI contrast enhancement through a multidimensional toxicogenomic profiling of gadolinium.. 2022 ,	2
78	Metal-Based Nanoparticle Magnetic Resonance Imaging Contrast Agents: Classifications, Issues, and Countermeasures toward their Clinical Translation. 2101710	0
77	Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.. 2022 , 96, 403	2
76	Comprehensive Speciation Analysis of Residual Gadolinium in Deep Cerebellar Nuclei in Rats Repeatedly Administered With Gadoterate Meglumine or Gadodiamide.. 2022 ,	
75	High-field magnetic resonance imaging: Challenges, advantages, and opportunities for novel contrast agents. 2022 , 3, 011304	0
74	Facile synthesis of superparamagnetic nickel-doped iron oxide nanoparticles as high-performance contrast agents for magnetic resonance imaging.. 2022 ,	2
73	Nanotechnology as a Versatile Tool for F-MRI Agent's Formulation: A Glimpse into the Use of Perfluorinated and Fluorinated Compounds in Nanoparticles.. 2022 , 14,	1
72	Contrast agents for MRI and side effects. 2022 ,	

71	Genotoxic effects of gadobutrol and gadoversetamide active substances used in magnetic resonance imaging in human peripheral lymphocytes .. 2022 , 1-12	0
70	Development of a Novel MR Colonography via Iron-Based Solid Lipid Nanoparticles.. 2022 , 17, 821-836	
69	Current Value of Biparametric Prostate MRI with Machine-Learning or Deep-Learning in the Detection, Grading, and Characterization of Prostate Cancer: A Systematic Review.. 2022 , 12,	2
68	MRI Contrast Enhancement Synthesis Using Cascade Networks with Local Supervision.. 2022 ,	0
67	Simultaneous Hemodynamic and Structural Imaging of Ischemic Stroke With Magnetic Resonance Fingerprinting Arterial Spin Labeling.. 2022 , STROKEAHA121037066	0
66	Intracranial Hemorrhage Following Anticoagulant Treatment in Denmark: Spontaneous Adverse Drug Reaction Reports Versus Real-World Data.. 2022 , 1	0
65	Hyperaccumulation of Gadolinium by AM1 Reveals Impacts of Lanthanides on Cellular Processes Beyond Methyloctrophy.. 2022 , 13, 820327	2
64	SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM).. 2022 , 1	1
63	Toxicological Impact of Rare Earth Elements (REEs) on the Reproduction and Development of Aquatic Organisms Using Sea Urchins as Biological Models.. 2022 , 23,	3
62	Dynamic susceptibility-contrast magnetic resonance imaging with contrast agent leakage correction aids in predicting grade in pediatric brain tumours: a multicenter study.. 2022 , 1	0
61	Deep learning-based contrast-enhanced MRI using cascade networks with local supervision. 2022 ,	
60	Characterization of commercial iron oxide clusters with high transverse relaxivity. 2022 , 10-11, 100054	1
59	Contrast-enhanced MRI: History and Current Recommendations. 15-19	
58	How the Chemical Properties of GBCAs Influence Their Safety Profiles In Vivo.. 2021 , 27,	0
57	Studying the Accumulation of Gadolinium in Human Brain Glioma for Gadolinium-Neutron Capture Therapy. 2021 , 85, 1445-1450	
56	Current approaches and advances in the imaging of stroke. 2021 , 14,	1
55	Cellular and molecular pathways underlying the nephrotoxicity of gadolinium. 2021 ,	0
54	Twenty Years of MRI safety: A Progress Report. 38-40	

- 53 Achieving Effective Multimodal Imaging with Rare-Earth Ion-Doped CaF Nanoparticles.. **2022**, 14, 2
- 52 Effects of Cations on HPTS Fluorescence and Quantification of Free Gadolinium Ions in Solution; Assessment of Intracellular Release of Gd from Gd-Based MRI Contrast Agents.. **2022**, 27,
- 51 Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure.. **2022**, 0
- 50 Metastatic spondylodiscitis in central venous catheter related bloodstream infections in hemodialysis patients: Risk factors and prognosis.. **2022**, 11297298221085460
- 49 CHAPTER 7. Molecular Imaging in Diagnosis and Treatment of Brain Tumours. **2022**, 207-241
- 48 Gadolinium retention in the tunica media of arterial walls - a complementary study using elemental bioimaging and immunogold staining.. **2022**,
- 47 Chronic kidney disease: CT or MRI?. 19-24
- 46 MRI in the era of nephrogenic systemic fibrosis: Review, controversies and suggestions for risk reduction. 22-33 6
- 45 Abdominal Computed Tomography Angiography. **2015**, 135-148
- 44 8. Polymeric MR Contrast Agents for Microvascular Imaging. **2022**, 78, 520-525
- 43 Gadolinium-Based Contrast Agents: Updates and Answers to Typical Questions Regarding Gadolinium Use. **2022**, 49, 0
- 42 Preclinical Profile of Gadoquatrane. Publish Ahead of Print, 0
- 41 Long-term Gadolinium Retention in the Healthy Rat Brain: Comparison between Gadopiclenol, Gadobutrol, and Gadodiamide. 0
- 40 Diagnostic Imaging Assessment of Tumor Vascular Involvement. **2022**, 551-575
- 39 Gray-Scale, Color Doppler, Spectral Doppler, and Contrast-Enhanced Renal Artery Ultrasound: Imaging Techniques and Features. **2022**, 11, 3961 0
- 38 Low-Molecular-Weight Fe(III) Complexes for MRI Contrast Agents. **2022**, 27, 4573 1
- 37 Gadolinium-free Magnetic Resonance Imaging of the Liver via an Oatp1-Targeted Manganese(III) Porphyrin. **2022**, 65, 9846-9857 0
- 36 Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager. **2022**, 12, 1816 0

- 35 Quiescent-Interval Single-Shot Magnetic Resonance Angiography May Outperform Carbon-Dioxide Digital Subtraction Angiography in Chronic Lower Extremity Peripheral Arterial Disease. **2022**, 11, 4485 ○
- 34 ED MRI: Safety, Consent, and Regulatory Considerations. **2022**, 30, 553-563
- 33 Physico-Chemical Characterization of a Highly Rigid Gd(III) Complex Formed with a Phenanthroline Derivative Ligand.
- 32 $55/52\text{Mn}^{2+}$ Complexes with a Bispidine-Phosphonate Ligand: High Kinetic Inertness for Imaging Applications. 1
- 31 Magnetic resonance contrast agents for neuroradiology. **2022**, 203-211 ○
- 30 Gadolinium retention in the ischemic cerebrum: Implications for pain, neuron loss, and neurological deficits. ○
- 29 Gadolinium and Bio-Metal Association: A Concentration Dependency Tested in a Renal Allograft and Investigated by Micro-Synchrotron XRF. **2022**, 8, 254 ○
- 28 Current advancement in the development of manganese complexes as magnetic resonance imaging probes. **2022**, 112018 2
- 27 Toxicity of rare earth elements: An overview on human health impact. 10, ○
- 26 12. Noncontrast MR Angiography. **2022**, 78, 1210-1216 ○
- 25 Manganese-Enhanced Magnetic Resonance Imaging of the Heart. ○
- 24 Feasibility of flow-related enhancement brain perfusion MRI. **2022**, 17, e0276912 ○
- 23 Cellular Toxicities of Gadolinium-Based Contrast Agents Used in Magnetic Resonance Imaging. ○
- 22 Was There Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occurring in Copenhagen. **2022**, 87-102 ○
- 21 Metal-organic frameworks: A promising option for the diagnosis and treatment of Alzheimer's disease. **2023**, 353, 1-29 1
- 20 Adjacent effect between gadolinium(III) and copper(II) in clay nanoparticles synergistically enhances T1-weighted magnetic resonance imaging contrast. ○
- 19 Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work. **2022**, 129-140 ○
- 18 Mn^{2+} Bispidine Complex Combining Exceptional Stability, Inertness, and MRI Efficiency. **2022**, 144, 22212-22220

- 17 α -Microglobulin Elevates COL5A1 mRNA in the Subsynovial Connective Tissue of Patients Receiving Hemodialysis With Carpal Tunnel Syndrome. **2022**, ○
- 16 Comparison of different analytical methods for speciation of seven gadolinium-based magnetic resonance imaging contrast agents and the applications in wastewater and whole blood. ○
- 15 Can magnetic resonance imaging after cranioplasty using titanium mesh detect brain tumors?. ○
- 14 The Optimal Echo Time Setting on Heavily T2-Weighted Fluid Attenuated Inversion Recovery Images for Detecting Very Low Concentrations of Gadolinium-Based Contrast Agent in the Brain: A Phantom Study. ○
- 13 MRI Contrasting Agent Based on Mn-MOF-74 Nanoparticles with Coordinatively Unsaturated Sites. ○
- 12 Manyetik Rezonans Kontrast Ajanların Sın Beyni Üzerine Etkilerinin Histopatolojik Değerlendirilmesi. ○
- 11 Non-Contrast-Enhanced MR Arteriography of Potential Living-Related Liver Donor: Using Contrast Enhanced CT Arteriography as Standard Reference. ○
- 10 The Potential of Gadolinium Ascorbate Nanoparticles as a Safer Contrast Agent. **2023**, 127, 346-358 ○
- 9 State-of-the-art of polymer/fullerene nanocomposites in biomedical field. **2023**, 211-250 ○
- 8 Manganese (II) Complex of 1,4,7-Triazacyclononane-1,4,7-Triacetic Acid (NOTA) as a Hepatobiliary MRI Contrast Agent. **2023**, 16, 602 ○
- 7 Skin Thickening of the Scalp and High Signal Intensity of Dentate Nucleus in Multiple Sclerosis. **2023**, 58, 223-230 ○
- 6 Harnessing Reconstructed Macrophage Modulation of Infiltration-Excluded Immune Microenvironments To Delineate Glioma Infiltrative Region. ○
- 5 Artificial Contrast. Publish Ahead of Print, ○
- 4 Gadolinium retention in a rat model of subtotal renal failure: are there differences among macrocyclic GBCAs?. **2023**, 7, ○
- 3 European fluxes of medical gadolinium to the ocean: A model based on healthcare databases. **2023**, 173, 107868 ○
- 2 Respiratory-Triggered Flow-Independent Noncontrast Non-ECG-Gated MRV (REACT) Versus Contrast-Enhanced MRV for Central Venous Evaluation in Children and Young Adults: A Six-Reader Study. ○
- 1 Contrast-Enhanced Cardiac Magnetic Resonance Imaging With a Manganese-Based Alternative to Gadolinium for Tissue Characterization of Acute Myocardial Infarction. **2023**, 12, ○